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The Lesotho Programme for Prevention of Mother-to-Child Transmission of HIV-1 (PMTCT) was 
launched in Lesotho in 2005. I joined the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) in 
2008, first as the Senior HIV Care and Treatment Advisor and subsequently, as Technical Director in 
the Lesotho program. I oversaw the PMTCT program implemented by EGPAF in six of the ten 
districts of Lesotho. In 2010, with additional funding from the United States Agency for International 
Development (USAID), EGPAF scaled up PMTCT services across the whole Kingdom of Lesotho. 
As part of my work, I was co-chair of the national PMTCT and pediatric HIV care and treatment 
technical working group (TWG). During this period, there were several changes to the PMTCT 
guidelines at both the global and national levels. As part of the TWG, we carried out site supportive 
supervision, during which we explored site-level data to understand if changes to the guidelines had 
the necessary impact on outcomes. However, we soon realized that, the real issue with PMTCT was 
not only the drug regimen, but the effectiveness of the program itself. For example, deoxyribonucleic 
acid polymerase chain reaction (DNA PCR) testing is recommended for early HIV diagnosis of 
infants at six to eight weeks of age to assess intrauterine and intrapartum HIV transmission. While 
the DNA PCR sample may be collected on-time in the facility, the laboratory system defines if the 
child’s caregiver receives the result on time to inform the course of further care for the child. In 
addition, traditionally, monitoring the results of infant HIV tests at six to eight weeks of age has 
continued to be the public health approach to measure PMTCT program effectiveness in many 
countries. However, in populations with high rates of breastfeeding among HIV-exposed infants 
(HEI), as recommended by World Health Organization (WHO), HEI continue to be at risk of HIV 
infection throughout breastfeeding period. This motivated me to conduct the studies upon which this 
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This thesis uses the following operational definitions: 
Caregiver: a person who provide essential care to a young child who has not reached the age of 
maturity. S/he can be biological parents, grandparents, other family relatives, or legal guardians. 
Conventional EID testing: Provision of early infant HIV testing for children in a centralized 
laboratory. 
HIV-exposed infant: A child who is born from an HIV-positive mother or who is being breastfed by 
an HIV-positive woman. 
Option B+: Provision of lifelong antiretroviral therapy to HIV-positive pregnant and breastfeeding 
women irrespective of their CD4 or WHO clinical stage. 
Point-of-Care Diagnosis: A test that can be provided in lower health facility or at the point where 






The number of new pediatric HIV-1 infections is reducing globally as services for the prevention of 
mother-to-child transmission of HIV-1 (PMTCT) are being scaled up. Lesotho has one of the highest 
HIV burdens globally with an estimated HIV prevalence of 25.7% in antenatal care (ANC). In 2013, 
the Ministry of Health of Lesotho adopted lifelong antiretroviral therapy (ART) for all HIV-positive 
pregnant and breastfeeding women, regardless of clinical or immunologic status (Option B+). 
Although this is expected to decrease mother-to-child transmission (MTCT) in general, program 
effectiveness data are only starting to emerge.  
In this thesis, I present results of three studies: conventional early infant diagnosis (EID) turnaround 
time (TAT); six-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants in the era of 
lifelong ART, and 18-24-month HIV-free survival measured through community survey. 
The overall aim of the study was to assess the effectiveness of the PMTCT program by determining 
birth outcomes and HIV-free survival of a prospective cohort of HIV-exposed infants compared to 
HIV-unexposed infants. In addition, we assess HIV-free survival among HIV-exposed children 
identified in the community who were born 18-24 months prior to study initiation. This was built on 
a baseline evaluation where we described turnaround time for EID when conventional EID was used.  
Methods: The baseline study was a retrospective cohort where data were abstracted from routine 
clinical records in health facility. The prospective observational cohort study included HIV-positive 
and HIV-negative women attending ANC and their infants up to 24 months postpartum; enrolled in 
the study June 2014 – February 2016. Study visits for HIV-positive mothers were three-monthly until 
24 months after delivery, while HIV-negative mothers had study visits every three to six months after 
delivery. Demographic, social, and medical data were collected from participants during clinic visits 
through interviews and extraction of medical record information. For the community cross-sectional 
study, we captured the mortality and HIV infection outcomes of HIV-exposed children who were 
born after the introduction of Option B+. 
For all studies, quantitative data analysis was performed using Stata. Categorical variables were 
summarized using frequencies and percentages of participants, while continuous variables were 
summarized using means and standard deviations or medians and interquartile ranges, as appropriate. 
Maternal baseline characteristics were stratified by HIV status. For the baseline study, turnaround 
time geometric means (with 95% CI) were calculated and compared using linear mixed models. For 
the prospective cohort study, we compared birth outcomes between HEIs and HIV-unexposed infants 
(HUIs). Categorical variables were compared using Chi-square tests and continuous variables using 
t-tests or Wilcoxon rank-sum tests, as appropriate. HIV-free survival was estimated as the proportion 
of children alive and HIV-negative among HEI. For the community cross-sectional survey, the 
difference in survival between subgroups was determined using the log-rank test.  
Results: Concerning the baseline study, of the total of 1,187 infants reviewed, the turnaround time 
was 61.7 days (95% CI: 55.3-68.7). The longest turnaround time was time of results from central 
laboratory to district hospital, 23.3 days (95% CI: 18.7-29.0). Mean times from specimen transfer to 
the central laboratory and for result transfer from central laboratory to district hospital were 
significantly shorter in the Lowlands Region (0.9 and 16.2 days, respectively), compared to Highlands 
Region (6.0 [p = 0.030] and 34.3 days [p = 0.0099]. 
Results of the cohort study showed that prematurity was more frequent among HEI, 7.8% vs. 3.6%, 
although there was no difference in rates of congenital anomalies between HEI (1.0%) and HUI 





and 1.0% (N = 6/583) (95% CI: 0.38–2.23) at six weeks. Among liveborn infants, six-week HIV-free 
survival for HEI was 95.6% (95% CI: 93.7–97.1).  
For the cross-sectional community survey, the MTCT rate was 5.7% [95% CI: 4.0-8.0] and the 
reported mortality rate was 2.6% [95% CI: 1.6-4.2] among HIV-exposed children compared to 1.4% 
(95% CI: 0.9 – 2.3) among HIV-unexposed children. The estimated HIV-free survival was 91.8% 
[95% CI: 89.2-93.8] among HEI. Disclosure of mother’s HIV status (aOR = 4.9; 95% CI: 1.3-18.2) 
and initiation of cotrimoxazole prophylaxis in the child (aOR = 3.9; 95% CI: 1.2-12.6) were 
independently associated with increased HIV-free survival while child growth problems (aOR = 0.2; 
95% CI: 0.09 – 0.5) were independently associated with reduced HIV-free survival. 
Conclusion: The turnaround study showed that average EID turnaround time was two months; the 
longest period of delay was transfer of results from central laboratory to district hospital. Meanwhile 
the prospective cohort study showed that implementation of universal maternal ART lowers MTCT 
at six weeks of age with no differences in congenital anomalies or early mortality between HEIs and 
HUIs. Of note, HEIs were reported to have high rates of prematurity. From the community cross-
sectional survey, despite scale up of lifelong ART among pregnant and breastfeeding women, HIV 






 The HIV life cycle 
HIV-1 replication starts as soon as the virus enters the human body (Figure 1). The host human cells 
must express CD4, a glycoprotein acting as a receptor found mainly on the surface of CD4+ T-
lymphocytes (often called ‘CD4 cells’ for short) but also on monocytes/macrophages and dendritic 
cells [1,2]. The replication of HIV-1 starts when the virus particle comes into contact with CD4 
glycoprotein. The viral surface protein gp120 sticks to CD4 and a co-receptor (chemokine receptor 
type 5 (CCR5) or the chemokine receptor type 4 (CXCR4) causing the viral envelop to fuse with the 
host cell membrane followed by release of the viral content into the host cell cytoplasm [3,4]. The 
reverse transcriptase enzyme immediately and reversely transcribes the viral ribonucleic acid (RNA) 
into deoxyribonucleic acid (DNA) which is transported into host cell nucleus to be integrated into 
human DNA by the viral enzyme integrase to form a provirus. One unique characteristic of HIV is its 
capacity to go dormant in the provirus state for a long time until when there is cellular activation. 
When activated, the provirus is transcribed into viral messenger RNA using human enzymes, then 
transported to the cytoplasm where the messenger RNA acts as blueprint for the production of new 
viral proteins, enzymes and viral particles. Viral particles, proteins and enzymes assemble into 
immature virions as the viral protease enzyme chops up long strands of protein to mature viral 
particles. The latter are capable to infect new host cells and the cycle starts all over again [5-8]. 
Once HIV infection is established, there is rapid multiplication of HIV in the body causing a large 
number of CD4 T-lymphocytes to be infected and destroyed (Figure 2). The destruction of CD4 cells 
is caused by several mechanisms induced by HIV cytopathic effects and include syncytial formation, 
cellular dysfunction, and apoptosis [9-11]. CD4 T-lymphocytes play a central role in the immune 
system. As CD4 T-lymphocytes are destroyed, there is rapid rise of the viral load with spread and 
seeding of the virus in many organs especially in the lymphoid system such as the spleen, lymph 
nodes, the thymus and gastrointestinal associated lymphoid system [10]. During this period, called 
‘the acute phase’, due to high circulating viral load in the peripheral blood and body secretion 
especially in the genital and anal areas, HIV infected individuals are very infectious [12-14]. The 
concentration of virus particles in the blood, called ‘viral load’ (VL) remains high for 10-12 weeks 
after the initial infection, during which there is irreversible destruction of the reservoir of CD4 T- 




for years. At the same time during this period, several individuals present with flu-like symptoms, the 






HIV blood VL gradually reduces to a low set point while the CD4 cells count bounds back but never 
to the initial level [16]. If the patient is not treated, the CD4 cell count slowly declines over time 
leading to increasing degree of immunosuppression. The patient will eventually develop opportunistic 
infections. These were initially used by World Health Organization (WHO) to make a clinical staging 
of the disease [17-19]. This staging is still in use. As the disease progresses, the patient is prone to 
life threatening conditions such as pneumocystis pneumonia, disseminated tuberculosis, cryptococcal 
disease and opportunistic cancers especially when the CD4 drops below 200 cells/mm3 [20,21].  
With the introduction of antiretroviral therapy (ART) and the scale up of treatment across the globe, 
the HIV disease progression has changed significantly. Once initiated on effective treatment, there is 
suppression of viral replication to an undetectable level (<40 copies/mm3) and CD4 recovery to almost 
initial pre-infection level [22-24]. The laboratory monitoring of HIV-positive patients is summarized 




 Burden of HIV disease in the world 
Since the first case of HIV was reported in 1981, more than 70 million people have been infected with 
the HIV virus [25]. In 2017, 36.9 million [31.1–43.9 million] people were living with HIV compared 
to 27.4 million [23.1–32.6 million] in 2000 (figure 3). This represents an estimated 0.8% [0.6-0.9%] 
of adults aged 15–49 years worldwide. The burden of the HIV epidemic continues to vary 
considerably between countries and regions; however, Africa continues to be home to 70% of those 
living with HIV [26, 27]. Women of reproductive age in Africa have higher HIV prevalence than men 




and 16.4 million (13.9-20.4 million) men are living with the virus, respectively [26, 27]. An estimated 
1.8 million (1.3-2.4 million) children aged 0-14 years are also living with the virus. Although HIV 
incidence is either stable or actually dropping in all age groups, among adolescents it has continued 
to rise with 1 million (0.54-1.5 million) female and 0.77 million (0.55-1.1 million) male adolescents 
living with HIV worldwide [26, 27].  
Table 1. Important laboratory tests for management of HIV infection. 










































































 Mother-to-child transmission of HIV-1 
HIV can be transmitted from an HIV-positive mother to her infant during pregnancy, delivery and 
postnatally through breastfeeding. In the era before treatment for HIV-positive women and 
prophylaxis for HEI, the estimated risk of MTCT was a) 5-10% during pregnancy; b) 10-20% during 
labor; c) 5-20% during breastfeeding [28]. Therefore, in the absence of any intervention, MTCT rates 
range from 15-30% in a non-breastfeeding population and 25-45% in a breastfeeding population. 
Factors associated with MTCT are shown in Table 2. 
A lot of progress has been made to reduce the risk of MTCT and in high-income countries, MTCT 
rates are below 2% [26]. In 2017, 80% of HIV-positive pregnant women received an intervention for 
PMTCT representing an excellent progress of more than 51% in comparison with PMTCT coverage 
in 2000, Figure 4 [26,27]. However, it is important to note that, close to 740,000 HIV-positive women 
of reproductive age became infected during 2016; 73% of whom are in 23 priority countries [26, 27]. 
In 2017, despite the roll out of lifelong combination ART in many countries, 180,000 children became 
HIV-infected; with over 90% being a result of MTCT [30]. MTCT rates in Africa vary from country 


































































































































































Figure 4, with data drawn from the Spectrum model, also provides estimates that suggest fewer 
pregnant women were living with HIV over the past decade (about 1.4 million vs. prior estimates of 
about 1.5 million). ARV coverage rates for PMTCT appear to have plateaued over the last three to 
four years [26, 27]. 
 The context of lifelong antiretroviral treatment 
The World Health Organization (WHO) has led the coordination of building guidelines for PMTCT 
based on the most up-to-date evidence. These guidelines have evolved since the publication of the 
first WHO PMTCT guidelines in 2001. The guidelines are built on public health principles to reach 
the highest number of patients with the most efficient treatment available, Table 3. In 2001, the 
guidelines recommended the provision of prophylaxis mainly to HEI with zidovudine (AZT) or 
zidovudine in combination with lamivudine (AZT/3TC) for four weeks or single-dose nevirapine 
(sdNVP) during labor [31]. 
In 2004, WHO reviewed and published guidelines for PMTCT with prophylaxis called combination 
or more efficacious regimen given to HIV-positive pregnant women with CD4 ≥200cells/mm3 from 
gestational age of 28 weeks as zidovudine monotherapy and during labor they are given sdNVP. All 
pregnant women with CD4<200 cells/mm3 were initiated on lifelong therapy as per the care and 
treatment guidelines for adults [32]. This was the first-time pregnant women were being given ART 







In 2006, based on the reported findings of high resistance to NVP among women after who received 
sdNVP, WHO reviewed the PMTCT guidelines to introduce coverage for “the non-reverse 
transcriptase inhibitors (NNRTI) tail”. So, women with CD>200cells/mm received AZT from 28-
week gestation, and sdNVP during labor and AZT/3TC for seven days after delivery [33]. 
In 2010, WHO decided to optimize PMTCT interventions for HIV-positive pregnant women. The 
new guidelines were based on an amalgamation of studies that demonstrated the efficacy of maternal 
ART during pregnancy and breastfeeding, or infant prophylaxis during breastfeeding to prevent 
MTCT in resource-limited settings [34-36]. The cut-off point for CD4 was increased to 350 
cells/mm3. For women with CD4>350; however, there were two streams of recommendation [37]: 
‐ Under Option A, HIV-positive women with CD4>350 cells/mm were initiated on AZT and 
3TC from14-week gestation, then sdNVP during labor and the infant given daily NVP until 
six weeks of life. 
‐ Under Option B, all HIV-positive women with CD4>350cells/mm3 were initiated on ART 
during pregnancy and throughout breastfeeding period. 
In 2013, WHO decided to make a single comprehensive document of “consolidated guidelines” for 























































Option B and increased the cut-off point for CD4 count to 500 cells/mm3. A major drawback of the 
Option B was that as soon as a mother stopped breastfeeding, she was supposed to stop ART only to 
start again as soon as she fell pregnant. In high-fertility areas, this created a lot of confusion. In 
addition, some mothers who were not eligible for ART for their own health, experienced 
immunological worsening of their disease and therefore became eligible for ART soon after stopping 
ART during pregnancy and breastfeeding. Therefore, WHO introduced Option B+ which initiated 
HIV-positive pregnant and breastfeeding women on lifelong ART irrespective of their CD4 cells 

















































These guidelines were then aligned with the WHO 2016 HIV treatment guidelines for HIV-positive 
patients which recommends lifelong treatment irrespective of CD4 cells count [39]. All children are 
given daily nevirapine or AZT/3TC for six weeks. One important point in the 2016 guidelines, is the 
use of VL to monitor treatment success. Therefore, HIV-positive pregnant or breastfeeding women 
on ART were expected to have VL done every six months. Ideally, all HIV-positive patients on ART 
were expected to have an undetectable VL (VL<40 copies/mm3) by six months after initiation of 
treatment and subsequently thereafter. In the public health approach, the term VL suppression was 




 General overview of the Kingdom of Lesotho 
The Kingdom of Lesotho – Lesotho, for short – is a mountainous, landlocked country located 
completely within South Africa in the Southern African region. Lesotho is a sovereign, democratic 
and independent nation. 
 
Figure 5. Administrative map of Lesotho. The capital Maseru is on the north‐western border [40].  
Lesotho, with the capital Maseru, was formerly known as the Basutoland and was renamed the 




1966. Lesotho is a constitutional monarchy and the current king (King Letsie III) has been head of 
state since 1996 [41, 42]. The latitudinal and longitudinal extent of the country is 29°30' South and 
28°30' East, respectively. The total length of its border is 909 kilometers and Lesotho has a surface 
area of 30,000 square kilometers, about 10% of the size of Norway or as large as the county of 
Vestland surrounding Bergen.  
Lesotho has four ecological zones (Lowlands, Foothills, Highlands, and the Senqu River Valley) and 
10 districts, namely Berea, Botha-Bothe, Leribe, Mafeteng, Maseru, Mohale’s Hoek, Mokhotlong, 
Qacha’s Nek, Quthing and Thaba Tseka [43]. Lesotho has four seasons: Spring (September 21st to 
December 20th); Summer (December 21st to March20th); Autumn (March 21st to June20th); and Winter 
(June 21st to September20th). Throughout the year, temperatures range from negative six degrees 
Celsius in winter to 35 degrees Celsius in summer. During winter, there is heavy snowfall, especially 
in the mountains. Lesotho has a population of 2.2 million with a population density of 64 persons per 
square kilometer, Table 4. The fertility rate in Lesotho is 3.09 births per women with a population 






















Lesotho is a middle-income country with a Gross Domestic Product (GDP) per capita of USD 




of the total budget on healthcare which still falls short of the Abuja Declaration recommendation of 
15%, but is higher than many other countries in the region [42]. 
 The health system in Lesotho 
Located in Maseru, the capital, the Lesotho Ministry of Health (MOH) provides overall leadership 
for the health sector. The mission of the MOH is to “provide an efficient and compassionate health 
care and social welfare system, with particular emphasis on the prevention and eradication of priority 
health and social welfare problems that are amenable to cost-effective intervention.” [43, 44]. the 
MOH plans to reach its mission through an effective and effective approach whereby affordable 
interventions with high health impacts are implemented in the country. Among others, the MOH 
coordinates formulation of policy, and stakeholder engagement during the consultation process for 
policy development. It sets standards and quality assurance, ensures capacity development for health 
care professionals to keep them abreast of international standards, provides supportive supervision 
and technical support to health facilities, and monitors and evaluates implementation of various 
national guidelines. The MOH also develops the budget for the health sector and ensures its 
appropriate implementation. However, in Lesotho, the MOH provides care to only 60% of the 
population while the remaining 40% receive their care from the Christian Health Association of 
Lesotho (CHAL), Figure 6 [45]. CHAL brings all churches together under one board to have 
concerted effort to provide health services. In recent times, the MOH signed a memorandum of 
understanding (MOU) with CHAL to provide funding to cover the cost of medicines and salaries for 
health care workers. In addition, there has been an increased presence of international non-
governmental organizations to support the MOH in fighting the HIV scourge. 
The national health structure consists of primary, secondary and tertiary levels of care. Currently, 
Lesotho has 372 health facilities including: 1 referral hospital, 2 specialized hospitals, 18 district 
hospitals, 3 filter clinics, 188 health centers, 48 private surgeries, 66 nurse clinics and 46 pharmacies 
[43, 45]. The first point of entry into the health system is the health center, which is the primary health 
care facility. The MOH owns 42% of the health centers, and 58% of the hospitals while CHAL owns 
38% of the health centers and 38% of the hospitals (Figure 5). The rest of facilities are owned by 
private practitioners who are located mainly in the districts of Maseru, Berea, Leribe, and Mafeteng 
[41, 45]. 
Figure 6 shows the distribution of public, not-for-profit health facilities in Lesotho. Private or for-







The primary health care level consists of health centers, health posts, and all community-level 
initiatives including all staff working at this level. There are village health workers (VHWs) who 
serve as the first point of contact for health with 40 household per VHW giving a total estimate of 
6,000 VHWs in Lesotho. At the district level, there are district hospitals and district management 
teams which are the secondary level of care and supervise health centers. The National Referral 
Hospital and the two specialized hospitals namely Mohlomi Mental Hospital and Bots’abello Leprosy 
Hospital constitute the tertiary level of care in Lesotho. Patients requiring more advanced care 
including cancer patients, patients requiring a transplant, etc. are referred to South Africa [45]. 
As demonstrated in the most recent survey data, individuals living in the urban/peri-urban settings 
have the highest access to and likelihood of using available health services [41, 46, 47]. Infant feeding 
practices also vary across the four ecological zones. 
 Antenatal care (ANC) 
The WHO now talks about positive pregnancy experience which is defined as: (a) maintaining 




(including preventing and treating risks, illness and death); (c) having an effective transition to 
positive labor and birth, and (d) achieving positive motherhood (including maternal self-esteem, 
competence, and autonomy) [48-50]. 
In Lesotho, there are various ANC interventions at different levels of care, Figure 7. In the figure, the 
maternal worker is a VHW who in this model accompanies the pregnant woman to facilitate her 
movement through the health system [51]. 
 
Figure 7. Schematic of the continuum of care for maternal health in Lesotho [51].  
In Lesotho, the focused antenatal care (FANC) approach, which requires four ANC visits during 
pregnancy, is the norm with more than 90% of women attending four ANC visits [52, 53]. Most 




based delivery is also high and most deliveries (70-85%) are attended to by skilled health workers 
[41, 53, 54]. Maternal and child health indicators have continued to improve after a deep dive during 
the initial phase of the HIV epidemic, before effective treatment was rolled out. In Lesotho hospitals 
and health clinics, once enrolled for care in ANC, pregnant women are assigned an ANC identification 
number that is recorded both in the register book and in the woman’s handheld card. The latter is 
brought by the pregnant woman to every visit. The ANC facility register contains the woman’s ANC 
identification number and demographic and pregnancy-related information. Table 5 shows the 





 The HIV situation in Lesotho 
The HIV epidemic in Lesotho is a generalized and mature epidemic, with heterosexual contact as the 
main transmission method. In addition, mobility of the population into South Africa in search of 
employment has been cited as one of the major factors [56, 57]. Since 2005, the government of 
Lesotho has considered HIV as national emergency because of the magnitude of the epidemic. 
According to UNAIDS, in 2018, HIV prevalence in Lesotho was 23.6% among the population aged 






top five population groups most affected by HIV are commercial sex workers, factory workers, men 
who have sex with men, prison inmates, and pregnant women with HIV prevalence of 71.9%, 42.7%, 
32.9%, 31.0%, and 25.9%, respectively [52, 58]. In 2016, the HIV prevalence among children aged 
0-14 years in Lesotho was 2.1% with 2.6% of girls infected compared to 1.5% of boys [47, 52]. In 
2018, there were 13,000 new HIV infections and 6,100 deaths among people living with HIV [52]. 
There are about 13,000 children living with HIV in Lesotho, over 95% of whom were infected 
vertically from their mothers. PMTCT has had a significant impact over the years and the number of 
newly infected children has reduced from 4,400 in 2009 to 1,300 in 2015 [41, 47, 52].  
The HIV prevalence also varies from district to district with the highest prevalence of 29.3% found 
in Mohale’s Hoek District and the lowest prevalence of 17.8% in Butha-Buthe District (Figure 8). 
Maseru District has the third highest HIV prevalence in pregnant women attending ANC and is the 
largest of the Lesotho’s 10 health districts. In the national ANC HIV Surveillance Report of 2018, 




The prevalence in various population categories varies by age and sex is shown in Figure 9. Women 
are infected at an earlier age than men and have the highest HIV prevalence (45.5%) between 35 and 





The Lesotho HIV epidemic has remained stable since 2004 with HIV prevalence of 23.4%, 23.0% 
and 24.6% in 2004, 2009 and 2014, respectively, Figure 10.  
Furthermore, the prevalence is much higher in urban areas compared to rural areas, 30.0% vs. 21.8%, 
respectively (Figure 11). This disparity is noted among women and men where women continue to 
have higher prevalence in both urban (35.6%) and rural (26.4%) areas compared to men who have a 










Factors contributing to HIV transmission in Lesotho include gender norms, multiple concurrent 
sexual partners, low use of female and male condoms, stigma and discrimination, internal migration 
from the mountainous rural areas to urban lowland areas, and external migration to South Africa. 
Among commercial sex workers (CSW) particularly, there are reports of high rates of sexual violence 




and abuse continue to fuel the epidemic [59-61]. The drivers of HIV epidemic in Lesotho have been 















HIV has had a devastating effect on Lesotho, making its population to drop from 2.2 million in 1986 
to 1.8 million in 2006 [64]. The country has continued to make great gains in care of people living 
with HIV. After the launching of the “Know your Status” campaign in 2000 by the King of Lesotho, 
testing rates increased rapidly. Among women, the coverage of HIV testing rose from 12% in 2004 
to 66% in 2009 and 84% in 2014 while for men, it has risen more slowly 9%, 37% and 67% in 2004, 
2009 and 2014, respectively [47]. This was coupled with the introduction of free ART in 2005 [59, 






 Prevention of mother to child transmission of HIV (PMTCT) in Lesotho 
The PMTCT program started in Lesotho in 2003 with the goal of universal access to PMTCT. Indeed, 
Lesotho has rapidly expanded its national PMTCT program to reach 100% facility coverage and over 
80% of women in need of services [55]. Over the years, Lesotho has aligned its national guidelines 

























The comprehensive approach to PMTCT has four prongs, Table 8. 
Lesotho began implementation of the adapted WHO 2010 PMTCT guidelines using “Option A” in 
2011 and transitioned from “Option A” of the 2010 WHO PMTCT guidelines to “Option B+,” 
meaning universal ART to all HIV-positive pregnant and breastfeeding women in April 2013 [54]. 
This is still the situation today. The guidelines provide a comprehensive package to pregnant women, 
Figure 13.  
The first-line ART regimen included in the 2013 Lesotho PMTCT guidelines consists of one 
combination pill taken once per day containing tenofovir 300 mg, lamivudine 300 mg, efavirenz 600 























































Pregnant women receiving ART should be monitored for possible medication side effects, efficacy 
of treatment, treatment failure, adherence and drug-drug interactions. Pregnant women receiving ART 
should be assessed clinically at 2 weeks, 1 month, 2 months, 3 months, 6 months and then at least 
every 6 months. VL should be checked every 6 months. Pregnant women receiving tenofovir should 
also have creatinine checked every 6 months [54]. Pregnant women on zidovudine-based regimens 
should have hemoglobin checked monthly.  
A Mother-Baby Pack (MBP) is offered to all pregnant women at their first visit to the ANC (Figure 
14). The MBP was designed to help address high rates of loss to follow-up (LTFU) during pregnancy 
due to weather, transportation and financial challenges. The pack is intended to simplify supply chain 
management and minimize treatment interruption due to stock-outs. Since the majority of women 
attend ANC at least once, the pack is provided at the first visit to maximize uptake of essential 
medications during pregnancy. Initially, three types of MBPs were developed: MBP1 for HIV-





























































































































































HIV-positive women on ART. However, in 2013 guidelines, the MOH maintained only 
MBP1 and MBP3 because there was no longer prophylaxis. 
 
Figure 14. Mother‐Baby pack,  (MBP). Counterclockwise  from  the  left.  (1) Outer pack 
identical  for all women.  (2)  Instruction  in  local  language  (Sesotho).  (3) Blue  inner box 
contains medicine  to  be  taken  during  pregnancy:  (i)  ferrous  sulphate,  folic  acid,  and 
Vitamin B‐complex for all women; (ii) ART for HIV‐positive women. (4) Yellow inner box 





Since the transition to Option B+, only the MBP packs for HIV-negative women on ART 
are administered. For HIV-positive women, they are offered the packs and they received 





The MBP1 includes medications provided to all pregnant women, including the following:  
 Ferrous sulfate 200 mg daily until 6 weeks post-partum 
 Folic acid 5 mg daily until 6 weeks post-partum 
 Vitamin B complex 2 tablets daily until 6 weeks post-partum [54] 
 Vitamin A 200,000 IU once 
A modified MBP3 is offered to HIV-infected pregnant women which contains a one-month 
dose of combination antiretroviral therapy and postnatal nevirapine prophylaxis for the 
infant. Mothers are instructed to bring the MBP with them to every ANC visit to allow for 
assessment of adherence, to collect the next months’ ART, and to return with her newborn 
7 days after delivery for a postnatal visit [54, 66]. In addition, mothers are instructed to 
return to the clinic with their infants at six weeks postpartum for HIV testing of the infant.  
The following ARVs are available for second-line use: tenofovir, abacavir, zidovudine, 
lopinavir/ritonavir and atazanavir/ritonavir. The recommended third-line regimen is 
raltegravir, darunavir/ritonavir and etravirine [67,68]. In 2019, Lesotho transitioned to 
dolutegravir-based first-line treatment. The national PMTCT Technical Working Group is 
working on the details of the various lines of therapy. 
The focus of the work of this thesis is in the full third and fourth prongs of PMTCT. As 
shown in Figure 13, the PMTCT services offered in Lesotho are a continuum and include 
ANC, intrapartum care, postnatal care for the mothers and the infants. In the ANC, 
pregnant women are offered HIV testing and counselling. HIV-negative women are given 
health education on the how to prevent HIV infection. This includes the use of condoms, 
and for those at higher risk of acquiring HIV, initiation of pre-exposure prophylaxis (PrEP) 
[67, 69]. High risk is defined as pregnant women in sero-discordant relationship where the 
sexual partner is HIV-positive while the women is HIV-negative or the partner does not 
know his HIV status [69]. Women found to be HIV-positive are enrolled into care in 





1. Clinical evaluation and WHO clinical staging. Although not mandatory, when 
available, women can have their CD4+ cells count done. 
2. Initiation on ART if she was not yet on ART before she became pregnant. Details 
of ART regimens have been discussed above. 
3. Safe obstetric practices. 
4. Psychosocial support for HIV-infected pregnant woman including healthy living, 
care of HEI (infant feeding). 
All HIV-positive pregnant women who are WHO clinical stage 3 or 4, or have CD4+<350 
cells/ml are initiated on cotrimoxazole [54, 67].  
For HIV-positive women, during the six-week postpartum visit by the mother-infant, the 
health care workers collect a DBS sample for PCR testing to determine the child’s HIV 
status. 
The WHO recommends that evaluations measure transmission at 6 weeks of age to indicate 
intrauterine and peripartum transmission, and at 18 months of age to indicate breastfeeding-
associated transmission [70].  
In summary, Lesotho PMTCT guidelines recommend rapid initiation of HIV-positive 
women on ART irrespective of their CD4+ cell count or WHO clinical staging. The 
Lesotho PMTCT guidelines recommend the following treatment options: 
(a) First-line: tenofovir, lamivudine and dolutegravir [TLD]. The alternate regimen is 
tenofovir, lamivudine, and efavirenz [TLE] or zidovudine, lamivudine and 
efavirenz. 
(b) Second-line regimen: zidovudine, lamivudine, and lopinavir boosted with ritonavir. 
The alternate regimen is tenofovir, lamivudine, and dolutegravir or lopinavir booted 
with ritonavir 




Treatment success is measured by VL testing. VL testing in Lesotho is done using the 
Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test quantitative test (v2.0) for which 
the limit of detectability is 20 copies/ml [54, 71-74].  
 HIV testing and counselling 
HIV testing and counselling constitutes the entry point for all pregnant women into the 
HIV care services cascade [53, 68, 75, 76]. Irrespective of where the clients take an HIV 
test (facility or community), it is important to link them to appropriate HIV care services 
if they are found to be HIV-positive. Currently in Lesotho, patients are offered group pre-
test information, then those who accept to undergo HIV testing are offered the test and 
those who are found to be HIV-positive are offered additional counselling with focus on 
positive health, dignity and prevention (PHDP) [75, 77, 78].  
In PMTCT, Lesotho introduced routine HIV testing for pregnant women in 2005, and in 
2010, the country chose the “opt out” strategy in which all clients presenting in ANC are 
offered HIV testing as part of package of services unless they explicitly decline to be tested. 
This has increased HIV testing with more than 97% of women in Lesotho accepting to be 
tested for HIV in ANC [68, 79-81]. Currently, the first test performed is the Determine™ 
HIV-1/2. Participants with a negative Determine assay are told their HIV-negative status. 
All participants who test positive will undergo a second test (with a new finger prick 
sample) using Uni-Gold™ Recombigen® HIV-1/2 and will be told their HIV-positive 
status if the second test is also positive [54, 68, 75, 82-85]. Those who test HIV-positive 
by the two initial tests will have a confirmatory test before being initiated on ART [82-85]. 
Figure 15 shows steps from HIV testing to linkage to treatment in Lesotho [68, 75]. 
 Postnatal care for HEI in Lesotho and monitoring of HIV-positive women 
Infants born to known HIV-positive mothers are identified as being HIV-exposed on the 
Child Health Card that is given to the mother during delivery. In the event that an infant or 
child attending the under-5 clinic does not have a known HIV exposure status, the national 




infant’s exposure status. Should the mother decline HIV testing, the infant should be tested 
for HIV antibodies to determine HIV exposure status. The revised 2013 guidelines 
recommend that all HEI be given NVP from birth or as soon as possible after birth for six 
weeks. In addition, HEI are given Cotrimoxazole from four to six weeks of age until HIV 
infection has been definitively excluded [54].   
 
Figure 15. HIV testing and linkage to ART (Adapted from [68] and [75]).  
Exclusion of HIV infection among infants requires direct viral testing, as HIV antibody 
testing by rapid tests is positive among HEI for a duration of time following birth due to 
the presence of maternal antibodies [54, 85, 86]. DNA PCR testing is recommended for 
use among infants less than nine months of age in Lesotho. HEI are tested for HIV by 
DNAPCR at 6 weeks and 14 weeks; and HIV antibody testing at 9 months and 18 months 
[54, 85-90]. Infants with a positive HIV test result are initiated on ART along while also 
undergoing a confirmatory HIV DNA PCR testing to confirm the initial positive result [54, 
68, 89-92]. Final documentation of the infant’s HIV status is conducted six weeks 
following cessation of breastfeeding using HIV DNA PCR testing among infants below 
nine months of age, or HIV rapid testing among infants above nine months of age [89, 90]. 
Children who test HIV-positive with rapid test undergo blood sample collection for HIV 




The schedule of services for HEI also includes routine medical care such as growth 
monitoring, administration of childhood immunizations, and de-worming. Follow-up visits 
are recommended for all children at 7 days, 6 weeks, 10 weeks, 14 weeks, 6 months, 9 
months, 12 months, and 18 months. In addition, HEI are expected to be followed on a 
monthly basis until 12 months of age, and every 2-3 months after the age of 12 months 
until final HIV status has been verified 6 weeks following breastfeeding cessation [54]. In 
addition, the EID cascade follows a complex pathway that may have bearing on the 
retention of HEI in care [54, 92-94]. The cascade is summarized in Figure 16 [95]. 
 
Figure 16. Step‐by‐step DNA PCR testing in Lesotho [95] 
In December 2016, Lesotho launched the point-of-care (POC) EID with outstanding impact 
on rapid turnaround time of results and early initiation of HIV-infected children on 





 Rationale and focus of the studies 
For more than 35 years, HIV has been a public health challenge and MTCT is the cause of 
more than 95% of pediatric HIV in the world [101-103]. In Lesotho, despite all the efforts, 
MTCT of HIV-1 contributes an important share of new cases of HIV. Of the 13,000 new 
HIV infections in Lesotho in 2018, it is estimated that 10% were from MTCT [26, 27, 55, 
104]. The Lesotho PMTCT program has been fully scaled up for more than ten years but 
has not yet reached elimination of MTCT of HIV-1 [104, 105]. While Lesotho has been 
forward thinking in developing policies and guidelines in line with international standards, 
there is a need for a continued collaboration between the health system and the community 
to facilitate access for pregnant women to effective care with optimal results. For example, 
any obstruction in the EID cascade will impact negatively in timely management of HIV-
infected children ultimately leading to high mortality [53, 104, 106, 107]. As recently as 
2012, collected dry blood spot (DBS) samples for EID from six to eight weeks old, HEI 
had to be transported from the health facility to the district laboratory and then to the central 
laboratory in Lesotho or outside the country. Once processed, test results had to be 
delivered to the district laboratory and then physically returned back to health facility 
making the full process quite complex. A detailed analysis of the pathway of EID using the 
traditional approach of collecting blood through the peripheral facilities and transporting 
them to a central laboratory and returning the results is important. This is important because 
we have to identify the bottlenecks in the health system and them in order to effectively 
and efficiently optimize EID cascade. Furthermore, there has been a lot of focus on the 
HIV transmission and treatment of HIV-infected children. A lot of progress has been made 
in this regard, and countries like South Africa are offering HIV testing for infants at birth 
and immediate initiation of HIV-infected infants on ART [108-111]. However, based on 
emerging data assessing the impact of HIV exposure in utero on HEI in term of birth 
outcomes, there is need for continuous generation of evidence especially for HIV-exposed 
children in the era of lifelong therapy [112-116]. It is important to elucidate whether the 




it will be ideal to further explore if HIV exposure increases the developmental risk, 
morbidity and mortality to HEI compared to HUI. In addition, studies have reported 
variable treatment suppression for HIV-positive women on ART and have cited HIV 
viremia during pregnancy, intrapartum and during breastfeeding as one of the key factors 
contributing the MTCT [117-119]. After introduction of lifelong ART (Option B+), and 
the VL monitoring of HIV-positive pregnant and breastfeeding women in Lesotho, the 
quality of care for this important priority population has continued to improve. There are 
remaining gaps that go beyond the use of ART for treatment success: women’s adherence 
has to be optimal and they have to be retained in care. One of the WHO-recommended 
methods for measuring PMTCT program effectiveness is the conduct of household surveys 
to document estimated transmission rates, HIV prevalence among children, and HIV-free 
survival [120, 121]. While literature the implementation Option B+ is limited, findings 
from Malawi suggest that women are more likely to be LTFU when starting on ART under 
Option B+ versus starting on ART for their own health [122, 123]. Household surveys from 
a three-country study found that 58.7% of breastfeeding women who did not know their 
HIV-positive status had VL levels above the suppression threshold of 1,000 copies/mL, 
increasing the likelihood of MTCT. Over half of these women had sought facility care 
during their pregnancy, tested HIV-negative in ANC, and had since sero-converted [124]. 
This incidental finding of HIV-positive pregnant and breastfeeding women poses a greater 
risk of HIV transmission to children thereby increasing the risk of HIV-related morbidity 
and mortality. Therefore, community household surveys may be a good approach to assess 
the effectiveness of PMTCT services in a holistic way.  
Several studies in Lesotho have focused on the VL monitoring in the general adult 
population or among children, and have reported results which may not necessarily be 
applicable to pregnant and breastfeeding women [125-127]. There is need to evaluate VL 





2.0 STUDY AIM AND OBJECTIVES 
 Aim 
The overall aim of this research was to assess the effectiveness of PMTCT approaches in 
resource-limited settings with focus on Lesotho and the effectiveness of the early infant 
cascade, outcomes of HEI in the context of lifelong ART and to assess treatment success 
of HIV-infected pregnant and breastfeeding women as measured by viral suppression. 
 Specific objectives 
1. To identify delays in the EID process from the time HIV specimens are collected at six 
to eight weeks of age to when caregivers receive the results and HIV-infected infants 
are initiated on ART at study sites (Paper I). 
2. To determine the effect of roll-out of lifelong ART on birth outcomes and the survival 
of infants born to HIV-positive mothers compared with a similar cohort of HIV-
negative mothers and their HUI (Paper II). 
3. To estimate MTCT rates, mortality, HIV prevalence, and HIV-free survival among 
children through a community-based survey among households with children born in 






3.0 SUBJECTS AND METHODS 
This thesis is based on three different studies, all focusing on the remaining challenges in 
the PMTCT program after the introduction of lifelong ART for all HIV-infected 
individuals. 
1. Paper I focuses on early infant diagnosis as a key step to measure PMTCT program 
performance.  
2. Paper II focuses on the birth outcomes of HEIs compared to HUIs.  
3. Paper III focuses on overall transmission rates and mortality in children 18-24 
months old.  
 Study designs and procedures 
An overview of the methodological aspects of each study is provided in Table 8. Below we 
present the designs and the procedures for each paper.  
Paper I. Turnaround time for EID samples  
We used a retrospective cohort design to analyze secondary data from health facility 
records using a step-by-step review of the pathway of samples for EID in order to 
understand the bottlenecks and calculate turnaround time (TAT) – the time from when the 
sample is drawn to when the results reach the mother.  
We studied samples from HEI at six to eight weeks of age who had a DBS sample taken 
for a DNA PCR test at the selected study sites between January 1st, 2011 and December 
31st, 2011, as identified in the EID laboratory records and by their mothers. In addition to 
the EID laboratory records, data on study women and infants were captured from routine 
PMTCT registers. A total of 1187 HEI records were reviewed for demographic 
characteristics including age, and sex of the child, use of ARVs for PMTCT, and maternal 
demographics. Then, these data were linked to mothers’ PMTCT records by their ANC 
identification number to capture demographics and PMTCT-related information, including 












































































































Information about initiation of HEI on NVP suspension was extracted from improvised 
registers. The database and registers were checked against each other throughout data 
collection as needed. We entered abstracted data into a paper-based standardized data 
collection tool. Once records had been matched, a study identification number was created 
using a code for the site and a non-identifiable numeric code that was not linked to the 
original patient number. The link between the patient identification number and the study 
identification number was recorded in a study enrollment log. The log and the completed 
data collection forms were kept at the facility in a locked location with controlled access. 
Data from the paper-based tool were entered into a password-protected database using the 
generated study identification number. As the principal investigator, I checked all data for 
completeness.  
Paper II. Six-week PMTCT outcomes for HEI and HUI 
We conducted a prospective observational cohort study with the aim to assess the 
effectiveness of the Lesotho MOH PMTCT guidelines to reach the goal of the virtual 
elimination of new pediatric HIV infections in selected sites in Lesotho as measured by 
HIV transmission rates and HIV-free survival among HEI.  
In this evaluation, we followed HIV-positive and HIV-negative pregnant women attending 
ANC during pregnancy and breastfeeding period and with their infants from June 2014 to 
February 2016. The mother-infant pairs were scheduled to come at least every three months 
for HIV-positive mothers and at least every 3-6 months among HIV-negative mothers and 
outcome for this analysis done at 6 weeks. HIV testing in HEI was conducted at four to six 
weeks of age, to assess if there had been any HIV transmission around birth. This provided 
an estimate of how effective the PMTCT program is at preventing HIV acquisition during 
pregnancy, delivery, and in the early postpartum period and whether there was any 
difference in birth outcomes between HEI and HUI. It allowed for determination of HIV-




The study population was pregnant women who attended ANC at a study facility, resided 
in the facility catchment area, and were willing to provide informed consent. We excluded 
pregnant women who were temporarily attending care at the study facility.  
We used sampling proportional to population to estimate the target number of participants 
at each facility. All pregnant women attending ANC were eligible for study enrollment, 
either into the HIV-positive cohort or the HIV-negative cohort. Informed consent was 
obtained from all participants using an informed consent document translated into the local 
language (Sesotho). Consent included permission to follow the participant in the 
community for study follow-up, including home visits and phone calls or SMS messages 
to check on the mother and baby (i.e., in-between visits) or if the mother-infant pair did not 
return for scheduled routine (or study) health care visits. Phone calls and SMS messages 
were made to a phone number of their choice, either shared or individually owned. Only 
neutral SMS messages were sent, without reference to HIV. Lack of access to a phone did 
not prohibit women from participating in the study. Participants were consecutively 
enrolled until the predetermined sample size is reached. 
Through interviews with the participants and extraction of information from clinical 
records during pregnancy, birth and six weeks postpartum, we collected socio-
demographic data and medical information.  
We entered abstracted data directly onto tablets. We used a range of source documents: 
Maternal bukana (health booklet) and infant health cards; ANC registers; delivery registers; 
under-five registers; laboratory results registers; ART registers and pharmacy 
registers/dispensing logs. We recorded the following: enrollment site, unique study 
identification number and mother/infant register numbers, and mother’s ANC number as 
patient identifiers in a study enrollment log and database to allow for linkage of patient-
level data across routinely used registers, logs, and forms. We entered all data on tablets 
by direct data entry into a study-specific database and stored on a secure, web-based server. 
Built-in data checks ensured that data were within a feasible range. Any out of range values 




completion. All electronic tablets were password protected, with access to only key study 
personnel. Tablets were maintained in a locked cabinet within a locked room when not in 
use by the appointed by study personnel, separate from any locator information. As the 
principal investigator, I carried out regular data collection monitoring and reviewed all 
procedures on site. 
As part of this study, we collected DBS from infants by heel prick, and spotted directly 
onto filter paper for HIV DNA PCR testing. We also collected blood samples (finger prick 
or venipuncture) of pregnant and breastfeeding women as per routine clinical practices that 
were part of the standard of care. All used lancets/needles were placed in a designated, 
labeled biohazards container that is approved for this use for disposal per routine 
procedures. All laboratory tests were processed per routine Lesotho MOH protocols for 
HIV antibody testing, HIV DNA PCR and HIV VL. These included infant diagnosis using 
the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 qualitative test (v2.0) and VL 
measurement with the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test 
quantitative test (v2.0).  
Paper III. HIV-free survival at 18-24 months of age 
We conducted cross-sectional community-based household survey with the aim to assess 
the population-based effectiveness of the Lesotho MOH PMTCT program to reach the goal 
of the virtual elimination of new pediatric HIV infections as measured by HIV transmission 
rates and HIV-free survival among HEI in selected districts. Paper III describes estimated 
MTCT rates, mortality, HIV prevalence, and HIV-free survival among children aged 18-
24 months. 
In this evaluation, we determined mortality and HIV infection as outcomes of the PMTCT 
program among HEI aged 18-24 months, who were born after the introduction of universal, 
lifelong ART for pregnant and breastfeeding women. This helped us to understand the 




of all breastfeeding. The community-based approach was utilized, as this age group is less 
likely to be seen at health facilities compared to younger infants.  
We selected the study population using a multi-stage process beginning with the selection 
of study facility catchment areas, followed by the selection of study communities, 
households, and finally study participants, Figure 17. 
 
Figure 17. Paper III study flow chart. 
In this study, we included mothers/caregivers and their infants aged 18-24 months and 
collected data from November 2015 and December 2016. We interviewed the 
mothers/caregivers in their language of choice using a structured data collection tool loaded 
on an electronic device with direct electronic data capture/entry. Once the child’s HIV 
exposure status was determined, the appropriate study activities was carried out. For 
women with documented HIV-negative status only the questionnaire was completed. More 




unknown HIV status. We collected data about demographics, use of health facilities for 
maternal and child health (MCH) and HIV services, maternal HIV status, maternal and 
infant receipt and use of ARVs during pregnancy and after delivery, infant feeding 
practices, and general well-being including growth and development. Information from the 
child health card and/or maternal health card was reviewed if available. The electronic 
devices for data collection had built-in data checks to ensure that data were within a feasible 
range. Data were stored temporarily on the device and regularly uploaded to the web-based 
server using a mobile internet connection. We reviewed all collected data for completion.  
 Study sites and description of the geographical setting 
In Paper I, we included 25 sites from all the 10 districts. Eleven of the sites were defined 
as hard-to-reach with long TATs in the range of six to eight weeks and they were from six 
districts: Butha Buthe, Qacha's Nek, Thaba Tseka, Mokhotlong, Maseru, and Quthing. An 
additional 14 sites were selected representing all 10 districts, the majority with shorter 
TATs of two to four weeks. The total number of sites comprised approximately 10% of the 































The data for paper II were collected in 3 of the 10 districts of Lesotho, namely Butha Buthe, 
Mohale’s Hoek, and Thaba Tseka. These districts were selected to ensure representation of 
PMTCT service delivery coverage, and heterogeneity in health-seeking behavior due to 
variances in terrain. We included all five hospitals in these districts and randomly selected 
nine medium volume health centers, Table 10. 
For paper III, 10 facilities from Maseru District and 5 facilities each from the districts of 
Butha-Buthe, Mohale’s Hoek and Thaba-Tseka were randomly selected, a total of 25 
facilities, Table 11.  
The four selected districts (Butha Buthe, Maseru, Mohale’s Hoek and Thaba Tseka) are 
representative of the variation in overall PMTCT service delivery coverage, and the 
heterogeneity in health care seeking behavior due to the varying terrain. The seven 
hospitals from the four districts included in the study covered a representative part of the 
health system. With a total population 940,000, the four districts account for nearly half of 
the total population of Lesotho. Between the four districts, there is a large variation of daily 
activities for a living. While in the mountainous districts of Thaba Tseka and Mohale’s 
Hoek the population are farmers, in the lowlands they tend to work in the textile factories. 
Health centers were classified into high, medium and low volume sites based on 2012 ANC 
attendance numbers. Low volume sites were excluded from the study because of the 
difficulty of recruiting enough women within the enrollment period.  
 Sample size, study outcomes and statistical analysis 
In paper I, the sample size for this study was based on feasibility and convenience since 
the aim was to describe the current EID process and MTCT infection rates and no 
intervention was introduced. From the national routinely collected baseline data, the 
available sample of infants who received EID HIV testing around six weeks of age in one 
year at the study sites was estimated to be approximately 2,675. The key outcomes were 




eight weeks or more; (b) Mean TAT from the time the DNA PCR sample is taken to the 
time the caregiver receives the test result among those who receive results; and (c) 









Maseru   Likotsi Filter Clinic  923  235  52 
Qoaling Filter Clinic  1438  366  80 
Domiciliary HC  281  72  16 
St. Leo HC  337  86  19 
Thaba‐Bosiu HC  356  91  20 
St Bernard HC  262  67  15 
St Joseph Hospital  704  179  39 
Koro‐koro HC  168  43  9 
St Barnabas HC  464  118  26 
St Rodrique HC  244  62  14 
Botha‐ 
Bothe  
Botha‐Bothe Hospital  307  78  17 
St Paul HC  292  75  17 
Ngoajane HC  141  36  8 
Tsime HC  197  51  11 
Linakeng HC  573  146  32 
Mohale’s 
Hoek  
Ntšekhe Hospital  807  205  45 
Mofumahali‐oa‐Rosari HC  385  98  22 
Ha Tšepo HC  380  97  21 
Morifi HC  275  70  15 
Mpharane HC  480  122  27 
Thaba  
Tseka 
Thaba‐Tseka HC  197  51  11 
St James Hospital  702  179  39 
Montmartre HC  275  70  15 
Mohlanapeng HC  249  64  14 
St Theresa HC  281  72  16 
Total    10718  2733  600 
 
We used SAS (SAS Institute, Cary, North Carolina, USA) for data analysis. Exploratory 
data analysis was done in order to allow us highlight general features of the data to direct 




CI) – time intervals (in days) were stratified by relevant independent variables. These were 
calculated with linear mixed models with the assumption of a compound symmetry 
working correlation structure to account for the clustering of women in facilities in order 
to determine the stages with the longest days (see Paper I for details). 
For paper II, we estimated the in-utero and peripartum HIV transmission rate to be 
approximately 4% at six to eight weeks under Option A based on our analysis of EID test 
results. As most HEI in Lesotho are breastfed, without ongoing prophylaxis throughout the 
breastfeeding period and depending on the type and timing of access to ARVs or even 
maternal HIV seroconversion during breastfeeding, an additional 0.16-1.57% of infants 
would acquire HIV infection per month during ongoing exposure to HIV through 
breastmilk [123]. At the time of the Option A implementation, the 2012 reported estimate 
of prophylaxis uptake during breastfeeding among mother-infant pairs was 19%, and 
approximately 45% of women who were eligible for treatment for their own health and 
were thought to have initiated ART in 2011. We used this to determine a range of 
transmission estimates and the required sample size [101, 123]. This sample size was 
derived to provide an estimate of the transmission rate across all three districts. Based on 
the number of pregnancies, HIV prevalence, and number of infants in the proposed 
districts, meeting the enrollment was considered feasible within approximately 12 months 
for the prospective cohorts. The estimated sample size was determined for the cohorts of 
HIV-positive and HIV-negative women based on the sample size necessary to measure the 
effect of the intervention on the primary endpoints. The sample selected was meant to allow 
us to determine the effect of the intervention with 80% power at 0.05 significance level, 
including adjustment for a design effect of 1.5 and a study LTFU of 20% (nQuery Advisor 
4.0).  
We enrolled 653 HIV-positive women and 941 HIV-negative women. Outcomes included: 
(a) birth outcomes including maturity, birth weight, and gross birth defects; (b) mortality; 
(c) HIV transmission; and (d) HIV-free survival at six weeks. For paper II we used Stata 




summarized using frequencies and percentages of participants while continuous variables 
using means (+/- standard deviation). We stratified maternal baseline characteristics based 
on HIV status at the time of enrollment into the study. Birth outcomes between HEI and 
HUI were compared. We estimated HIV-free survival as the proportion of children alive 
and HIV-negative among all HEI. The precision around survival estimates was assessed 
by 95% confidence intervals. Kaplan Meier curves were used to graphically display infant 
mortality, infection, and HIV free survival. For paper II specifically, the infection rate was 
calculated as the proportion of infants with a positive HIV test result by six weeks among 
HEI. Confidence intervals were estimated for both infection proportion and infection rate.  
For paper III HIV-free survival among 9-24-month-old infants was estimated to be 91.9% 
with a precision of 1.4%. Assuming HIV-free survival among 18-24-month-old HIV-
exposed infants was lower than the estimate from Rwanda, due to less extensive PMTCT 
coverage in Lesotho in comparison to Rwanda, in order to determine HIV-free survival 
with 3% precision around the point estimate, we needed to identify 545 HEI [124]. 
Adjusting the sample size by 10% for miscellaneous events (e.g., missing data, consent to 
some but not all study activities) we estimated a total sample size target of 600 HEI. Given 
the HIV prevalence of approximately 25.4% among pregnant women in ANC, we would 
need to visit or approach 2,363 households of infants or mother-infant pairs within the 18-
24-month age range to identify 600 HEI. To account for approximately 15% refusals to 
participate in this component of the study and interviews with non-maternal caregivers of 
HIV-exposed children (who may not be able to adequately answer questions needed to 
address the research aims) we needed to visit approximately 2,700 households to reach the 
required sample of HEI and their mothers. We used Stata (StataCorp LLC, College Station, 
Texas, USA) for analysis. Categorical variables summarized using frequencies and 
percentages; continuous variables were summarized using means (standard deviations), or 
medians (interquartile ranges) as appropriate. HIV-free survival was estimated as the 
proportion of children alive and HIV-negative among all HIV-exposed children with a 




were differences in HIV-free survival between subgroups. Multivariate logistic regression 
models to test the independent association of ANC attendance, mode and place of delivery, 
gestational age at birth, birth weight, maternal vital status, adherence to and timing of 
initiation of antiretroviral drugs, infant feeding method and nutritional status with HIV-
free survival among HIV-exposed children. 
 Ethical considerations 
Ethical approval was sought and obtained from the Lesotho Ministry of Health Research 
and Ethics Committee (REC), the Baylor College of Medicine Children’s Foundation 
Lesotho Institutional Review Board (IRB), the George Washington University Committee 
on Human Research IRB and the Regional Committees for Medical and Health Research 
Ethics in Norway.  
Waiver of consent was obtained for abstraction of data that contributed to paper I, and 
written consent was obtained from participants who participated in the studies for paper II 





4.0 SUMMARY OF RESULTS 
 Paper I Turnaround time for samples for EID 
Out of the 1187 HEI, 92.8% of the mothers had ART for PMTCT or treatment and at the 
time of review, the maternal mortality was 6.9% (82/1187). The mean infant age at the 
time of the sample was taken for DBS was 46.9 (±3.4) days. Of the 47 (3.9%) HIV-infected 
children, 36 (76.6%) were initiated on ART. The children were initiated on ART at an 
average of 1.3 days (95%CI: 0.3–5.7; range: 10–56) after receiving results. Considering 
the fact that some of the results were communicated by phone, some children were initiated 
on treatment before the parents physically received the results. The mortality rate among 
children at the time of review was 1.4% (17/1187) with the status of children who died not 
known. 
The mean total turnaround time was 61.7 days (95%CI: 55.3– 68.7), Figure 18. The longest 
time spent by the specimen and results occurred at stage 3, which is the time from receipt 
of specimen at the central laboratory to receipt of results at district hospital, and it was 23.2 
days (95% CI: 18.7–28.9). The average stage 1 and stage 3 time-intervals were 
significantly shorter in the Lowlands Region (0.9 and 16.2 days), compared to Highlands 
Region (6 days [P = 0.03] and 34.3 days [P < 0.01] (See Figure 19 below). The mean 
turnaround time was 47.4 (95% CI: 39.0–57.7) and 62.4 (95% CI: 55.6–69.9) for HIV-
infected and HIV-uninfected children, respectively. The mean (95% CI) turnaround time 
(in days) calculated from a linear mixed model including test result, region and facility 
level, was found to be significantly shorter for HEI compared to HUI 















 Stage  5:  Time  from  receipt  of  results  at  health  facility  to  results  receipt  by 
caregiver: 10.4 days (95% CI: 7.9‐13.5)  
 Total time: 61.7 days (95% CI: 55.3, 68.7)  
 Paper II 6-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants  
Of the 653 HIV-positive women enrolled, 623 HIV-positive women gave birth to 631 HEI 
while 868 HIV-negative women of the 941 HIV-negative pregnant women enrolled gave 
birth to 879 HUI, Figure 19. HIV-positive women were significantly older than HIV-
negative women with a mean age of 28.7 (+/- 5.5) compared to 24.4 (+/- 5.7) years and 
they presented for ANC earlier than the HIV-negative women at a mean gestational age of  




























23.0 (+/- 8.7) weeks compared to 25.3 (+/- 8.2) weeks. 97.8% of HIV-positive women were 
receiving ART at enrollment 40.2% of whom initiated ART before conception and 59.8% 





Ineligible (477) Ineligible (197) 
Not enrolled (150) Not enrolled (71) 


















No 6-week info (16) 
Stillbirths (19) 
Deaths (27) 
No 6-week info (2) 




Concerning birth outcomes, 91.6% of study women delivered in a health facility with 
96.8% of infants born alive. Although not statistically different, HIV-positive women were 
more likely to have had a macerated stillbirth, compared to HIV-negative women who were 
more likely to have had an intrapartum death. The risk of a preterm birth was twice as high 
among HEI compared to HUI (7.8% vs. 3.6%) while the risk of very preterm birth 
(gestational age <32 weeks) was considerably higher among HEI compared to HIU (2.2% 
vs 0.4%). Low birthweight (<2.5 kg) was 11.6% among women who initiated ART before 
conception compared to 11.9% among women who initiated ART after conception. 
Furthermore, very low birthweight (<1.5 kg) was 1.7% among women who initiated ART 
before conception compared to 1.2% among women who initiated ART after conception.  
The estimated survival rates were 94.8% (95% CI: 93.1–96.1) among HUI and 94.0% (95% 
CI: 91.8–95.7) among HEI when including stillbirths as deaths. There was no difference in 
survival rates at 6 weeks of age by infant HIV exposure status. When considering postnatal 
deaths alone (excluding stillbirths), the estimated survival rates were 96.8% (95% CI: 95.4–
97.9) and 96.7% (95% CI: 95.0–98.0) for HUI and HEI, respectively. Adjusting for 
maternal mortality and gestational age at first ANC visit, infant HIV exposure status was 
not associated with early infant mortality (aOR = 1.06, 95% CI: 0.56–1.99). 
Focusing on HEI, the estimated HIV transmission rate among those tested at birth was 
0.9% (95% CI: 0.25–2.36) and by six weeks the overall HIV transmission was 1.0% (95% 
CI: 0.38–2.23). The estimated HIV-free survival including stillbirths was 92.8% (95% CI: 
90.5–94.8), and 95.6% (95% CI: 93.7–97.1) when stillbirths were excluded. At six weeks, 
the mortality rate was much higher among preterm babies, 24.6% (17/69) compared to term 
infants 2.1% (29/1391). The mortality at six to eight weeks was much higher among low 
birthweight infants compared to normal birth weight infants (7.0% vs. 1.9%). Very low 
birthweight infants had higher risk of death within six to eight weeks compared to infants 





 Paper III HIV-free survival at 18-24 months of age 
Figure 20. Study profile for Paper III. 
Of the 11,169 households screened, 2,190 were eligible in which 1,852 mothers/caregivers 
consented to participate in the study. There were 1,882 deliveries including 64 twin births 
in the households which met the inclusion criteria (born 18-24 months prior to the time of 
data collection), Figure 19. Of the biological mothers, 424 were known to be HIV-positive 
while 39 additional women were diagnosed as HIV positive during the study of whom 38 
had tested HIV negative during pregnancy. Overall, 95.8% and 80% of mothers had 




HIV-positive women, 94.7% had disclosed their HIV status to someone and 59.9% had 
disclosed to their sexual partner. Note: Of the 338 households that declined to participate, 
the following reasons were provided: caregiver, child or both were unavailable (n=178), 
(157 of whom were at work); lack of time to participate (n=71); no incentive provided 
(n=25); not comfortable to participate (n=16); caregiver did not feel they had enough 
information to answer questions (n=15); mother needed husband’s permission (n=9); 
caregiver was below 18 years of age (n=6); and other reasons (n=18). 
The estimated HIV transmission was 5.7% (95% CI: 4.0-8.0). The estimated child 
mortality was 2.6% (95% CI: 1.6-4.2) among HIV-exposed children compared to 1.4% 
(95% CI: 0.9 – 2.3) among HIV-unexposed children. The majority of child deaths occurred 
after the neonatal period. Among the HIV-exposed children, HIV-free survival was 91.8% 
(95% CI: 89.2-93.8). Disclosure of mother’s HIV status (aOR = 4.9, 95% CI: 1.3-18.2) and 
initiation of cotrimoxazole prophylaxis to the child (aOR = 3.9, 95% CI: 1.2-12.6) were 
independently associated with increased HIV-free survival while child growth problems 
(aOR = 0.2, 95%CI: 0.09 – 0.5) was independently associated with reduced HIV-free 
survival.  
Of the children, 9.1% were reported to have been preterm. HIV-exposed children had a 
slightly higher rate of preterm births compared to HIV-unexposed (9.9% vs. 9.0%). The 
mean (±SD) birthweight was 3.02 (0.5) kg. HIV-exposed infants had marginally lower 
birth weight compared to HIV-unexposed, 2.9 (0.6) vs. 3.05 (0.5) kg. Of the children, 
95.2% were breastfed with an overall median duration (IQR) of 12 (7-18) months. The 
HIV-exposed children had a shorter duration of breastfeeding compared to the HIV-
unexposed, 11 (6-12) months vs. 15 (10-18) months. Fewer HIV-exposed children 
breastfed for more than 18 months compared to the HIV-unexposed (9.1% vs. 17.1%). Of 
the 37 children who were reported dead, 16 were born to HIV-positive women. 
There was no difference in timing of deaths between HEI and HUI among the 28/37 
children whose mothers/caregivers reported timing of death, Table 12. Half of the children 


















Within first day  5  1  2  8 
Within 28 days  3  3  0  6 
After 28 days  7  7  0  14 















22  1  ‐  23 
Initially HIV‐negative, but 
HIV‐positive at 18‐24 months 
5  ‐  ‐  5 
Newly diagnosed HIV‐positive 
at 18‐24 months 
3  ‐  2  5 
Total  30  1  2  33 
 
Of the 33 children who were HIV-positive, 10 were diagnosed during our study, Table 13. 
Of the children newly diagnosed with HIV, two were from women who tested HIV-positive 
during the study, three were born to known HIV-positive women, but had never been 
tested, while five who were also born to known HIV-positive women who had initially 
tested HIV-negative as part of their care but had not had their confirmatory tests done at 
the time of the study. Of the HIV-positive women, 86.8% used ART during pregnancy and 
37.6% of mothers of the children who were HIV-infected started ART either during or after 
the breastfeeding period compared to 9.6% of mothers of HIV-uninfected children. Among 
HIV-positive women, 88.0% reported that they were still taking their ARVs at the time of 
the study. 89.3% of HIV-exposed children had received nevirapine prophylaxis. Twelve of 





The results presented in this thesis shows that the prevention of mother-to-child 
transmission of HIV goes beyond provision of ARVs. It involves health systems, women’s 
participation in their own health and that of their children, appropriate monitoring of HEI 
to diagnose HIV and improve health outcome and accurate methodologies in measuring 
MTCT rates. 
The first study showed the need to optimize EID to provide early initiation of treatment for 
children who are HIV infected (paper I). It is not enough that the child is HIV negative 
after birth, which has been the focus of many PMTCT programs in the past. The child has 
to remain alive while free of HIV. This starts with tracking the birth outcomes of HIV-
exposed infants and ensuring their survival beyond the neonatal period (paper II). Building 
on the successes of ART scale-up among HIV-positive pregnant women and in line with 
the WHO recommendations, the effectiveness of a PMTCT program needs to be assessed 
by measuring HIV-free survival at the end of breastfeeding period when HEI is no longer 
exposed to the virus. Assessing HIV-free survival at 18-24 months of life is a good 
approach to achieve this (paper III). 
 Discussion of results 
In the first study, we found that, although children presented to care for HIV testing on 
time, the overall TAT until the caregivers received the results was over two months. The 
longest delay – more than three weeks – was from the time of receipt of specimen at the 
central laboratory to receipt of results at the district hospital. Importantly, the overall TAT 
was significantly shorter for HIV-infected children compared to HIV-uninfected children. 
In addition, the second study showed that pregnant women in Lesotho continue to present 
late in the second trimester with HIV-positive pregnant women presenting earlier than the 
HIV-negative women. The rate of preterm birth was higher among HEI compared to HUI. 
There was no difference in rates of congenital anomalies between HEI and HUI. HIV 
transmission was 0.9% at birth and cumulative transmission of 1.0% at six weeks. The 




respectively. Preterm and low birth weight babies were more likely to die than term and 
normal weight babies, respectively. Among liveborn infants, six-week HIV-free survival 
for HEI was comparable to survival among HUI. After adjusting for maternal mortality 
and gestational age at first ANC visit, infant HIV exposure status was not associated with 
early infant mortality. Finally, in the third study, we found that the MTCT HIV-1 rate was 
5.7% in birth whose mothers were initiated in care in the era of lifelong ART including 
those who sero-converted after initially testing HIV-negative. The mortality rate was 
almost as twice as high among HIV-exposed children compared to HIV-unexposed 
children. HIV-free survival was 91.8% [95% CI: 89.2-93.8] among HEI. Disclosure of 
mother’s HIV status and initiation of cotrimoxazole prophylaxis in the child were 
independently associated with increased HIV-free survival while child growth problems 
were independently associated with reduced HIV-free survival. 
Looking at Lesotho, a country with the second highest HIV prevalence in the world, it is 
important to ensure children who are HIV-exposed receive HIV testing on time, while child 
survival strategies are in place to improve birth outcomes and HIV survival beyond the 
neonatal period. It is sad to see that there has been no reduction at all in the adult HIV-
prevalence over 10 years, which means we are continuously allowing new generations of 
adolescents to become infected with HIV.  
5.1.1 EID as a key step in the care of HIV-exposed infant 
At the time of the study for paper I, Lesotho, like many countries in sub-Sahara Africa, 
continued to see the age of children who get the first DNA PCR test to be more than six 
months of life [128-132]. Paper I described the comprehensive process from a heel-prick 
to the results getting back to caregivers and eventually the HIV-infected child being 
initiated on ART. This was the first time this kind of analysis was done in Lesotho. In this 
study, based on the conventional system of processing DNA PCR in a centrally located 
laboratory, we found that major delay occurred at the central laboratory (fig 19). This is a 
major issue because the delay in the health system impeded directly in the decision to care 




care may cause up to half of them to die by their second birthday [133]. This is still the 
case in several countries in Africa [130, 131, 134]. In our study, the children generally 
presented on time for the EID test and the delay was mainly in the health system. This is 
contrary to the situation reported from Tanzania, where late presentation of the children 
was reported as the main cause of delay in early infant diagnosis [135]. There is, therefore, 
a need to rethink the health system for EID, if we are serious in wanting to reduce the infant 
mortality linked to HIV infection. In a country like Lesotho, considering the impact of 
geographic location of health facilities in the TAT, it will be key for the MOH to either a) 
improve transport of specimens and return of results in a timely manner, or b) decentralize 
the capacity to process DNA PCR in the district laboratory or c) introduce POC diagnosis 
for nucleic acid testing. Recent studies have shown that the introduction of POC technology 
reduced the TAT for EID significantly compared to conventional techniques [136-138]. 
This has been a great development but it brings a new layer of challenges, which are related 
to supply and distribution of cartridges, storage requiring refrigeration, and staffing and 
technical maintenance of the machine.  
The other important finding was the fact that HIV-infected children received their results 
earlier and most of those who had a record about their ART initiation were rapidly initiated 
on treatment. Further exploration showed that the health workers had an understanding that 
HIV-infected children had higher rates of morbidity and mortality. Therefore, they 
instituted initiatives to contact caregivers of HIV-infected children over the phone. This 
appeared to be successful, however, health care workers did not do the same for HEI who 
had a DNA-PCR negative result. Of course, various studies have reported mixed reactions 
from health care workers about contacting caregivers in relation to children’s EID results 
[139, 140]. Considering the fact that there is HIV-related stigma in Lesotho, health workers 
calling caregivers may indirectly disclose the status of the mother to whoever receives the 
phone call. In addition, several caregivers prefer to come back to health facilities to collect 
their child’s results during their own ART collection appointment [141-144]. Considering 




countries in the region, they could serve as a liaison to reach out to caregivers once their 
child’s results are ready in countries where conventional EID is still in use. 
5.1.2. Maternal and child health services: the platform for successful PMTCT 
The integration of HIV testing services in ANC has over the years revolutionized HIV care 
for pregnant and breastfeeding women. Once the HIV status is known, documented and the 
HIV-positive woman is appropriately counselled; the earlier she is initiated on ART, the 
better the woman’s health outcome, and the lower the VL at the time of delivery, thereby 
reducing the risk of HIV transmission to her HEI.  
The importance of outcomes among HIV-exposed children has been a topic of high interest 
in recent times. In our second study, we felt that the first step should be to consider birth 
outcomes and outcomes during and immediately after the neonatal period.  
We found similar birth outcomes for HEI and HUI, except that the frequency of preterm 
delivery was higher among HEIs. This is an important finding because of the additional 
care required for preterm infants is causing additional strain on the family and the health 
system [145, 146]. This further compound the health challenge related to HIV-infection 
itself and the chronic use of ART. These results call for additional monitoring of the HEI 
beyond the neonatal period where we consider health complications among preterm 
children as they grow [145]. While the risk for preterm birth among HEIs has been reported 
in other studies, there have been limited studies conducted in routine health systems that 
have large numbers of both HIV-negative and HIV-positive women in the era of lifelong 
ART with TDF-based ART regimens. In our study, low birth weight and preterm delivery 
did not statistically differ between women who initiated ART before conception and those 
who initiated after conception. This aligns with other studies that found no relationship 
between preterm delivery and preconception ART [146].  
We also found a high rate of ANC attendance reported by the women participating in our 
study above the 77% reported in the 2014 Lesotho Demographic Health Survey. Similarly, 




finding because when pregnant women attend ANC and deliver in a health facility, it 
reduces the risk of pregnancy and delivery complications and HEI are more likely to be 
given antiretroviral prophylaxis. And even if there are complications, the health team then 
has time to plan a proper management of the woman and the baby including EID [147-
149]. Not surprising, most of the women who had HIV-infected children at six weeks had 
unsuppressed VL.  
In our study, we found that that although there was no difference in the proportion of infant 
stillbirths among HIV-positive women compared to HIV-negative women, HIV-positive 
women were more likely to have had a macerated stillbirth versus fresh still birth which 
was found among HIV-negative women. The high number of macerated stillbirths is 
consistent with challenging quality of antenatal care in the country especially lack of 
optimal monitoring of HIV-positive pregnant women. This calls for close monitoring of 
the HIV-positive pregnant women as high risk pregnant during ANC, labor and delivery. 
Of note, in a study in India, there was higher intrauterine fetal deaths among HIV-positive 
pregnant women compared to HIV negative (AOR = 1.9; p < 0.01) [150-152].  
5.1.3. Completion of PMTCT cascade is key to measure PMTCT effectiveness 
In our third study, we found that 38 of the 39 women who newly tested HIV-positive had 
seroconverted since they tested HIV-negative during pregnancy. This calls for 
reinforcement of HIV re-testing for pregnant and breastfeeding women in countries with 
high adult HIV prevalence like Lesotho. Furthermore, this raises some questions whether 
these women knew their partners’ HIV status [152]. Based on current guidelines, if these 
women were in a HIV sero-discordant relationship, PrEP should be proposed [153]. 
In addition, at the time of the study, we found that 88.0% of HIV-positive mothers reported 
currently taking ART with 89.3% of HEI receiving NVP prophylaxis within three days of 
delivery. At the time of the interview, more than 10% of women were no longer on ART 
and more than 10% of HEI did not receive NVP prophylaxis. This is an important finding 




transmission [154]. Although some leaks could be due to maternal or child mortality, there 
is a need to explore measures that can be used to retain at least 95% of patients in care in 
accordance to global target.  
5.1.4. Late HIV diagnosis among HIV-exposed children 
Timely diagnosis of children will foster earlier ART initiation, thereby reducing morbidity 
and mortality. In our Paper III, one-third of HIV-infected children were diagnosed during 
the study with half of those having tested HIV-negative earlier. This, further buttresses the 
need for subsequent repeat tests for HEI. 
Furthermore, HIV-free survival is a better approach to measure the PMTCT effectiveness 
because it does not only measure the effectiveness of ART to reduce the MTCT rate, but it 
also shows how PMTCT services built on the MCH platform are able save young children’s 
lives and measure early deaths among HEI [29, 38, 155-157]. 
 Strengths and limitations of the methods and design 
One strength in this thesis work is that we used the most appropriate methods for data 
collection for this setting. The retrospective cohort data abstraction collected data from a 
real-world setting. This method produced our baseline and identified the real challenges 
faced by the health system. The study participant interviews during the observational 
prospective cohort coupled with clinical record abstraction within research sites gave the 
opportunity to control for some of the challenges noted in the retrospective cohort. Finally, 
the community-based household interviews with community-based HIV testing provided 
a comprehensive assessment of the program. This method of data collection was used to 
ensure that women who did not attend ANC or were lost to follow up were assessed. And 
methods used for data collection operated in the real world to give results that are 
applicable to general program settings. 
A second strength is that all the studies had large sample sizes, which made the descriptive 










































































1187 HEI, the TAT for the results of children who were HIV-positive was significantly 
shorter than those who were HIV-negative (p<0.001). In the observational cohort sub-
study, although there was no difference in birth outcomes between HEI and HUI up to six 
to eight weeks, when followed up to 24 months, HEI had higher mortality than HUI (Log-
rank p<0.001). Finally, in the large community sample, HIV-free survival among HEI was 
reliably assessed in Lesotho. 
A third strength is that the study sites were drawn from several sites in Lesotho. For 
example, for paper I, the sites of the study were from all the ten districts. Although some 
hard to reach sites were excluded, the studies’ findings could be generalized to the entire 




country. In addition, the studies for paper II and III took into consideration the geographical 
and social determinants of health-seeking behaviors in Lesotho. Sites were selected to 
represent the highlands, the foothills and the lowlands making the results applicable to 
these settings. A larger sample size in a quantitative study makes results more generalizable 
[158]. 
A retrospective cohort – also called a historical cohort – is a form of observational cohort. 
A major interest in this study was the assessment of the TAT of EID from sample collection 
to caregivers receiving results and initiating HIV-infected children on treatment. For us to 
get the true picture of the TAT of EID in Lesotho, it was essential to track each step DBS 
specimens went through. It would have been impossible to carry out this study 
prospectively and get the true picture without influencing the health system and the results, 
the so-called Hawthorne effect. Therefore, the best design was retrospective cohort in 
which we followed the circuit of a number of samples [159]. The advantages of the 
retrospective cohort design as stated by Sedgwick; minimized selection bias, minimized 
recall bias and possibility to estimate population at risk applied clearly in our study. The 
challenge observed in our study with this design was that, we used records that were not 
designed for the study, therefore the available data had issues with quality. There was 
limited data on potential confounding factors. Differential losses to follow-up can also bias 
retrospective cohort studies. In order to address this challenge, we used data from several 
sources so that each variable could be verified.  
In addition, we had an interest to know whether birth and six-week outcomes among HEI 
was different from those observed among HUI. An observational prospective cohort 
indicates the sequence between exposure and outcome over time. By definition in this 
design, at the beginning of the study, it is known that subjects do not suffer from the 
disease. In our case, we had comparison group as HUI. The advantage is that cohort studies 
allow you to calculate relative risk or ratio which was important in our study. In addition, 
prospective cohort studies reduce the possibility that the results will be biased. In our study, 




cost and the risk of LTFU. Concerning the cost, the study was imbedded as part of a large 
project, which was well resourced. The challenge of potential loss to follow-up (LTFU) 
was mitigated by ensuring scrupulous implementation of the intervention to track mother-
infant pairs according to national standards [160]. 
The cross-sectional design requires a single interaction between study participants and the 
data collection team. There are indeed reduced chances to of LTFU compared to cohort 
studies. Compared to other designs, the cross-sectional design is less expensive and is 
importantly faster to conduct. Since the sample is taken from the whole population it 
estimates the prevalence of the outcome of interest. It gives an opportunity to asses 
outcomes and risk factors. Our study for paper III used this design because it was the most 
adapted option in the context. The disadvantages include a difficulty to make causal 
inference and data represents only a snapshot in a timeframe that may change quite quickly. 
There is a prevalence-incidence bias (also called Neyman bias). By definition, prevalence-
incidence bias occurs when the patients with severe or mild disease are excluded, resulting 
in an error in the estimated association between an exposure and an outcome. Excluding 
the patients who have died will make the disease condition look less severe than it should 
be while excluding the patients who will recover from the disease will make the condition 
look severe. And in the case of HIV being a chronic disease and the fact that our primary 
outcome was a composite outcome that included HIV transmission and death, results that 
included deaths might have been under-represented [160-162].  
The studies also had limitations and we will touch on the most important ones here.  
For paper I, while this study focused primarily on the health facility and laboratory delays 
with regards to EID processes, in-depth information on mother-infant pairs’ access to 
PMTCT services and reasons for LTFU were not comprehensively captured. However, this 
study yielded important information on barriers to early diagnosis and treatment for HEI, 
such as transport and reporting systems and postnatal follow-up of HEI, and where best to 
target interventions to ensure children who test positive are promptly provided with life-




information in registers, missing files, and laboratory results that were not copied into 
records. This limitation motivated the design of the study for paper II which had the 
opportunity to put in place additional support to study sites. 
For paper II, since the study measured birth outcomes and six-week HIV-free survival in a 
facility-based population, we may have missed women and children who did not seek care 
in health facilities and women who lost pregnancies early. That is why we carried out the 
third sub-study in community which informed the results presented in paper III.  
For paper III, the limitation might have been the difficulty to accurately measure deaths in 
the community because of the discomfort of the parents may have felt to report death 
infants. However, when put together, the three papers bring wealth of data which presented 






 Long TAT for EID have constituted a major bottleneck for timely initiation of HIV-
positive children on ART. Innovative approaches, such as point of care testing, are 
currently being tested and is likely to be part of the solution to this problem.  
 The implementation of universal ART in Lesotho continues to have a significant 
impact in reducing HIV transmission to children and was associated with low 
MTCT by six weeks of age, with no differences in congenital anomalies or early 
mortality between HEIs and HUIs. 
 The community survey showed that Lesotho has achieved a high utilization of MCH 
services by pregnant women. The use of PMTCT services from testing to enrolment 
on ART is high, resulting in HIV-free survival for HIV-exposed children at 18-24 
months comparable to other countries in the region.  
 Of the children diagnosed with HIV at the age 18-24 months in the community 
survey, one-third were diagnosed for the first time during our survey, partly due to 
new infections in the adult population, which calls for:  
o reinforced efforts to control the adult epidemic  
o innovative ways to prevent postnatal MTCT 





 Recommendations to policy makers 
 All countries with centralized EID system where TAT is counted in weeks or even 
months, need to consider the introduction of POC EID. 
 The MOH needs to put in place a system to fast-track blood specimens and results 
to ensure timely return of results to patients for expedited care for HEI or infected 
children. 
 Government needs to consider support strategies for intensive care for HIV-positive 
pregnant women as they should be classified as high-risk pregnancy.  
 The MOH needs to consider reinforced efforts to control the adult HIV, also among 
women during pregnancy and breastfeeding. 
 
 Recommendations for research 
 As the expansion of PMTCT services in the context of lifelong ART continues, we 
recommend the establishment of observational cohorts across many countries with 
regional data centers to measure long term health and survival of HEI in Africa 
beyond 24 months. 
 Considering the importance of community household surveys, it is recommended 
that researchers repeat surveys sequentially at two-three-years-intervals to measure 
the true impact of PMTCT services over time. 
 MTCT occurs even in women who tested negative during antenatal due to sero-
conversion during pregnancy or breastfeeding period. As we implement strong 
PMTCT services, new infections in children will be driven by seroconversion 
among HIV negative pregnant and breastfeeding women, therefore, we need to 
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Early infant diagnosis is an important step in identifying children infected with HIV during the
perinatal period or in utero. Multiple factors contribute to delayed antiretroviral treatment ini-
tiation for HIV-infected children, including delays in the early infant HIV diagnosis cascade.
Methods
We conducted a retrospective study to evaluate early infant diagnosis turnaround times in
Lesotho. Trained staff reviewed records of HIV-exposed infants (aged-6-8 weeks) who
received an HIV test during 2011. Study sites were drawn from Highlands, Foothills and
Lowlands regions of Lesotho. Central laboratory database data were linked to facility and
laboratory register information. Turnaround time geometric means (with 95% CI) were cal-
culated and compared by region using linear mixed models.
Results
1,187 individual infant records from 25 facilities were reviewed. Overall, early infant diagno-
sis turnaround time was 61.7 days (95%CI: 55.3–68.7). Mean time from specimen collection
to district laboratory was 14 days (95%CI: 12.1–16.1); from district to central laboratory, 2
days (95%CI 0.8–5.2); results from central laboratory to district hospital, 23.3 days (95%CI:
18.7–29.0); from district hospital to health facility, 3.2 days (95%CI 1.9–5.5); and from health
facility to caregiver, 10.4 days (95%CI, 7.9–13.5). Mean times from specimen transfer to the
central laboratory and for result transfer from central laboratory to district hospital were sig-
nificantly shorter in the Lowlands Region (0.9 and 16.2 days, respectively), compared to
Highlands Region (6.0 [P = 0.030] and 34.3 days [P = 0.0099]. Turnaround time from blood
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draw to receipt of results was significantly shorter for HIV infected infants compared to HIV
uninfected infants [p = 0.0036] at an average of 47.1 days (95%CI: 38.9–56.9) and 62 days
(95%CI: 55.9–68.7) respectively. Of 47 HIV-infected infants, 36 were initiated on antiretrovi-
ral therapy at an average of 1.3 days (95%CI: 0.3, 5.7) after caregiver received the result.
Conclusion
HIV-infected infants received results earlier and were rapidly initiated on antiretroviral ther-
apy once the result was delivered to caregiver. However, average early infant diagnosis
turnaround time was two months; the longest period of delay was transfer of results from
central laboratory to district hospital. Turnaround time of results based on geographical
regions or between hospitals and health centres varied but did not reach statistical
significance.
Introduction
Multiple factors contribute to delayed antiretroviral treatment (ART) initiation for HIV-
infected children, including service delivery gaps in early infant HIV diagnosis (EID) [1–3].
Despite advances made in the field of prevention of mother-to-child transmission (PMTCT)
of HIV, the average age of initiation of treatment for HIV-infected children is approximately
five years [3,4]. Though there are multiple reasons for this, poor access to infant HIV testing
and diagnosis is one key barrier. While EID access has improved, only 51% of the 1.6 million
HIV-exposed African children had access to EID testing in 2015[5]. Approximately 23% of
Lesotho’s population are living with HIV, making it among the highest per capita HIV infec-
tion rates in the world [4,5]. Of the approximately 310,000 individuals living with HIV in Leso-
tho, 13,000 are children < 15 years of age [6,7].
The Lesotho Ministry of Health (MOH) guidelines for EID are consistent with the World
Health Organization (WHO) guidelines, recommending that the first virological test for
infants exposed to HIV should be conducted at or around 6 weeks following birth, and all
infants diagnosed with HIV should be started on ART immediately irrespective of CD4 count
[8,9]. However, there are still gaps in coverage for EID/Early Infant Treatment (EIT) services
in Lesotho, especially in rural areas [10]. In a study in Uganda, it was found that EID coverage
was 16% (101/636); 4.5% (8/179) and 20.3% (93/457) in rural and urban health facilities
respectively [11]. Similar gaps were reported in South Africa [12].
As of 2013, more than 50% of exposed/infected children did not receive their results within
2–4 weeks and approximately 30% of infants were lost to follow-up (either not enrolled into
care or retained in care) in Lesotho [9]. The pathway from sample collection to results received
was multifaceted and a delay in one point influenced the overall efficiency and TAT of the pro-
cess. At the time of the study, the utilized pathway had several steps that could cause significant
delays. While EID can be conducted using a variety of virologic assays, in Lesotho, EID is con-
ducted using a DNA polymerase chain reaction (DNA-PCR) assay. At the six-week postpar-
tum visit, HIV-exposed infants received a physical examination and immunizations and a
dried blood spot (DBS) sample was taken for DNA-PCR testing to determine the child’s HIV
status. Collected DBS samples were transported from health facilities to the district laboratory
(referred to as the district hub); for visits at district hospitals, the laboratory was on the same
campus. The specimen was then sent to laboratory headquarters (central laboratory) for
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personnel to decide whether the specimen should be processed at the central laboratory in
Maseru or sent to another laboratory in South Africa for processing. This decision was based
on the origin and quality of the sample. The national laboratory in South Africa operated an
automated system while at the time of the study, the Lesotho National reference laboratory
operated a manual system that was replaced by an automated system. For specimens to be sent
to South Africa, the blood spot must be within the demarcated circle otherwise it had to be
processed in Maseru. In addition, high volume facilities such as hospitals had their specimens
sent to South Africa. At the time of the study, the proportion of specimens sent to South Africa
for processing varied from one third to about half. Once processed, test results were delivered
back to the district hub and then returned to the health facility. Caregivers were typically
advised to return to the health facility after four weeks from the date of child’s blood draw.
However, when some caregivers returned and test results were not yet available, they might
not return to the health facility again to collect their infants’ test results. Additionally, some
patients did not return to the health facility for other reasons and were then lost to follow-up.
Furthermore, for children who were diagnosed as HIV-infected, test results were sent electron-
ically to health facilities through 3G mobile internet and short message service (SMS). Com-
munity health workers actively track HIV-infected children back to the health facility within
seven to ten days to enable them to be initiated on ART in accordance to national guidelines.
As the guidelines call for testing and treating all those living with HIV including children,
there is an increasing need to scale up HIV diagnosis especially among infants and children
[9]. Lesotho has made great strides in rolling out a national PMTCT program and the current
mother to child transmission of HIV (MTCT) rate is estimated at 5.9% [7]. There are limited
data that analyze the EID cascade to demonstrate barriers to efficient EID in sub-Saharan
Africa, especially in a country with diversified topography like Lesotho. This paper describes
the EID process and identifies bottlenecks within the EID pathway by tracking the length of
time for each step in the cascade.
Materials and methods
Study design
We conducted a retrospective cohort study with the aim to describe the EID process in order
to identify the barriers and delays within the EID pathway by tracking the length of time for
each step. To determine where the delays existed between steps in the EID pathway, we esti-
mated the average time intervals between the following time points:
• The 6-8-week HIV specimen is collected at the facility,
• The specimen is sent to the laboratory,
• The laboratory received the specimen,
• The laboratory processes the specimen and obtains results,
• The laboratory sends the results back to the facility,
• The facility receives the results from the laboratory,
• The facility contacts the caregiver,
• The caregiver receives the results,
• The HIV-infected infants are initiated on ART at study sites.
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The variability for each time interval was estimated and compared between caregivers
within sites (mean of the variances) and between sites (variance of the means). The characteris-
tics of facilities were purposively predetermined based on topographic location as highlands,
foothills and lowlands, which determine health seeking behaviour in Lesotho.[6] Unique char-
acteristics of sites with the shorter time intervals were identified and compared to the sites
with longer time intervals.
Study population
Trained study staff abstracted data from the national laboratory database on all HIV-exposed
infants who had a DNA-PCR EID test at 6–8 weeks of age from January to December 2011 in
25 sites from all 10 districts in Lesotho. Data abstracted from the database included infant
age, test result, district hub and dates when the tracked specimen was received and pro-
cessed. Using the child’s name and other key information, infants’ database records were
linked to facility records from which their mothers received care. The records included the
DNA-PCR EID test result, antenatal care (ANC), and ART registers and laboratory docu-
mentation. From these records, limited mother and infant demographics, mother and infant
ARV regimens, and additional dates that documented the specimen and result along the EID
pathway were abstracted. The documented dates reflected the physical receipt of the speci-
men and the results. During the study time, all sites were using 3G mobile internet and short
message service (SMS) to communicate some of the results, especially results that were HIV-
positive. The 3G mobile internet and the SMS systems were rolled out as part of project sup-
ported PEPFAR through the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). Once
the results were sent to health facilities, electronic records as email were kept in the EGPAF
head office in Maseru. Study staff also completed a data collection form which documented
information about each facility, including characteristics, such as distance to district hub and
mode of transport for samples, and strategies for identification and follow-up of mother-
exposed infant pairs.
Study sites
25 sites were included in this study. Of these 25 study sites, 11 were health centers that were
purposively selected, and were defined as hard-to-reach.[6] Of these 11 hard-to-reach, 8 facili-
ties were located in the highlands and presented a challenge during winter when roads are
blocked with heavy snow fall. These 11 facilities were located in six districts, each representing
the three geo-topographical areas of Lesotho as follows: Highlands (Mokhotlong, Qacha’s Nek,
Thaba Tseka); Foothills (Butha Buthe and Quthing); and Lowlands (Maseru). Program data
showed that the hard-to-reach sites had longer TATs estimated at 6–8 weeks. An additional 14
sites were selected from all 10 districts of the country in order to represent more typical TATs.
The topographical distribution of these 14 sites was as follows: Highlands (Mokhotlong,
Qacha’s Nek, Thaba Tseka) 3 sites; Foothills (Butha Buthe, Leribe, Mohale’s hoek and
Quthing) 6 sites; and Lowlands (Berea, Mafeteng, Maseru) 5 sites. The majority of these latter
sites had estimated TATs of 2–4 weeks. Study sites included 16 health centers and nine
hospitals.
Data collection and analysis
Data were collected in March–April 2012 and entered into MS Access (2007–2010). The ANC
identification number was used to link laboratory and facility records. Once records had been
matched, a study identification number was created using a code for the site and a non-identi-
fiable numeric code that was not linked to the original patient number. The link between the
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patient identification number and the study identification number was recorded in a study
enrolment log. The log and the completed data collection forms were kept at the facility in a
locked location with controlled access. Following study completion, these documents were
destroyed. Data from the paper-based tool were entered into a password protected database
using the generated study identification number, which were then imported into SAS for sta-
tistical analysis. Data were analysed at the EGPAF/Lesotho office in Maseru and EGPAF
Global in Washington, DC.
Steps along the EID pathway were categorized into five stages. Stage 1 was the time from
specimen collection to transfer to district laboratory. Stage 2 was the time from specimen
receipt in the district hub to transfer to central laboratory for testing. Stage 3 was time from
receipt of specimens at the central laboratory to receipt of results at district hospital. Stage 4
was the time from receipt of results at the district hospital to receipt at health facility. Stage 5
was the time from receipt of results at health facility to results receipt by caregiver.
For this study, we conducted an exploratory data analysis using numerical and graphical
methods to display important features of the data, an analysis for each objective and its associ-
ated variables, and a descriptive data analysis. Exploratory data analysis allowed us to highlight
general features of the data to direct future analyses and identify problem areas in the data.
The average–geometric mean (95% CI)–time intervals (in days) were stratified by relevant
independent variables. They were calculated with linear mixed models assuming a compound
symmetry working correlation structure to account for the clustering of women in facilities in
order to determine the stages with the longest days.
In order to explore variations in TAT at study sites, for the purpose of this study, mean
TATs (based on TAT for the caregiver) was categorized as long, (median 75.5–99 days),
medium (62.5–67 days), or short (33.5–60 days).
Since this study was a retrospective review of existing records, there was no consent
involved and the ethics committee waived the need for consent. This study received approval
from the Baylor College of Medicine Children’s Foundation, Lesotho institutional review
board and the Lesotho national research and ethics committee.
Results
Characteristics of the study population (mothers and infants)
In this study, 1187 HIV-exposed infants’ records were reviewed. The mean (standard devia-
tion, SD) maternal age at the time of the delivery was 28 (±5.6) years.
Table 1 describes characteristics of the mothers and infants whose records were reviewed in
this study. 92.8% of women received antiretroviral (ARV) drugs for PMTCT or treatment:
33.4% received antiretroviral therapy (ART) for their own health; 44.2% received zidovudine
for prophylaxis against transmission; and 15.2% received an unknown ARV regimen. Maternal
death rate at the time of review was 6.9% (82/1187).
The mean (SD) infant age at blood draw was 46.9 (3.4) days. The HIV transmission rate at
6–8 weeks in the study participants was 3.9%. Of the 47 children who were HIV-infected, 39
had records of ART status, with 36/47 (76.6%) initiated on ART. The 36 children were initiated
on ART at an average of 1.3 days (95%CI: 0.3–5.7; range: 10–56) after result receipt (in some
cases children who tested positive were tracked outside the conventional system and contacted
by phone, with some initiated on ART before they received the physical result through the
conventional system). Overall 17/1187 (1.4%) of children had died at the time of review. The
HIV status of children who died was unknown.
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Turnaround time analysis
S1 Fig shows mean times that specimens and results took at each stage of the EID cascade.
Overall, the mean total turnaround time in this sample of sites was 61.7 days (95%CI: 55.3–
68.7). The longest time spent by the specimen and results occurred at stage 3, which is time
from receipt of specimen at the central laboratory to receipt of results at district hospital, and
was 23.2 days (95%CI: 18.7–28.9). The average stage 1 and stage 3 time intervals were signifi-
cantly shorter in the Lowlands Region (0.9 and 16.2 days), compared to Highlands Region (6
days [P = 0.03] and 34.3 days [P = 0.00].
The mean turnaround time was 47.4 (95%CI: 39.0–57.7) and 62.4 (95%CI: 55.6–69.9) for
HIV-infected and HIV-uninfected children, respectively (Table 2). The mean (95% CI)
Table 1. Mother and infant characteristics.







Maternal ART regimens during pregnancy
ARV for prophylaxis 525 (44.2)
ART prior to index pregnancy 161 (13.6)
ART initiated during index pregnancy 156 (13.1)
None 86 (7.2)
ART unknown when initiated 79 (6.7)





















Calculated interclass correlations (ICCs) for all variables and all were close to zero. These variables are not
facility dependent. Note: ART: antiretroviral therapy; ARV: antiretroviral; EID: early infant diagnosis.
https://doi.org/10.1371/journal.pone.0184769.t001
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turnaround time (in days) calculated from a linear mixed model including test result, region
and facility level (Table 3), was found to be significantly shorter for HIV-infected infants com-
pared to HIV-uninfected infants (p<0.01).
Overall, the turnaround time of results based on geographical regions (Highlands, Foothills
and Lowlands) or between hospitals and health centers varied but did not reach statistical
significance.
Discussion
In this study we found that the major contributor to health system delays in turnaround time
in the EID cascade in Lesotho was the time from receipt of specimen at the central laboratory
to return of results to district laboratory (Stage 3), followed by the time for transfer of speci-
mens from health center to district laboratory hub (Stage 1). Although HIV-exposed infants
are brought to the clinic at an average of seven weeks of life to have blood drawn for their
6-weeks DNA-PCR EID test, it took over two months for their caregivers to get the results
back. In our step-by-step analysis, the longest delay occurred within the laboratory chain. In
fact, even though it took two weeks to get the DBS samples from the collection point to the
Table 2. Turnaround time (TAT) for the stages in the EID cascade calculated from linear mixed models.




All infants at 6–8 wks
N (%) Mean TAT in
days (95%CI)
N (%) Mean TAT in
days (95%CI)
N Mean TAT in
days (95%CI)










2 Specimen transfer from
district laboratory






2.0 (0.0–552.6) 247 2.0 (0.8–5.2)
3 Specimen transfer to
central laboratory
Time results transferred from central












4 Result receipt at district
hospital




3.2 (1.8–5.8) 513 3.2 (1.9–5.5)
5 Result receipt at health
facility




10.8 (8.2–14.2) 879 10.4 (7.9–13.5)



















Positive 37 (4.2) 47.1 (39.0–57.0)
Negative 850 (95.8) 62.0 (55.9–68.8)
Region 0.057
Highlands 77 (8.7) 63.6 (51.8–78.1)
Foothills 401 (45.2) 54.6 (46.0–64.8)
Lowlands 409 (46.1) 45.5 (37.3–55.5)
Facility Level 0.21
Hospital 710 (80.0) 57.7 (48.9–68.2)
Health centre/filter clinic 177 (20.0) 50.6 (43.1–59.4)
https://doi.org/10.1371/journal.pone.0184769.t003
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national central laboratory, it took more than three weeks to get the results back to district lab-
oratories. This may be caused by the system focusing primarily on getting blood specimens
from HIV-exposed infants while neglecting that the EID cascade is only complete when results
get back to the caregiver. The main bottleneck in the EID cascade was the central laboratory.
Our data are similar to the findings of a study in Uganda, where a median turnaround time
of EID at 39 days was found [13]. Together these findings point out that scale up of HIV ser-
vices is not always accompanied by health system strengthening to absorb the additional bur-
den that may occur with scale-up, including the laboratory system [14,15]. The effectiveness of
PMTCT can only be achieved if HIV-exposed infants’ caregivers get results of their HIV status
in a timely manner and children who are HIV-infected are initiated on ART [16–18]. In addi-
tion, children who are not HIV- infected at this early stage can continue to be monitored while
they receive the much needed child survival package to reduce the risk of death from other
childhood illnesses.
In our cohort of 6–8 weeks’ old infants, the HIV prevalence was below the targeted HIV
MTCT-elimination rate of 5%. This result can be attributed to significant coverage of interven-
tions for PMTCT in this study population, with over 90% coverage of maternal and neonatal
ARV prophylaxis or treatment. This is encouraging but must be interpreted with caution. In a
population where majority of the women breastfeed their infants such as in Lesotho, it is rec-
ognized that a significant number of children may still get infected throughout breastfeeding
[15,19,20]. In April 2013, Lesotho adopted lifelong ART for all HIV-infected pregnant and
breastfeeding women regardless of CD4 cell count or WHO clinical staging, ahead of the June
2013 WHO guidelines for PMTCT [9, 21]. The gains of this kind of policy change can only
become a reality if the health system, including the laboratory network, is strengthened to
ensure timely collection and processing of EID specimens and timely return of results to care-
givers [20,22].
Our data demonstrated that, when the infants’ HIV status was considered, HIV-infected
infants received their results in significantly shorter time. In addition, health care workers
were requested to reach the caregivers of children who have a positive HIV DNA-PCR EID
test result directly by phone. Children with positive results were required to be seen and initi-
ated on treatment within seven days after communicating with the caregiver. Importantly,
many of the children were initiated on treatment after the health facilities received their elec-
tronic results, well ahead of receiving the printed copies of the results. As part of overall pro-
gram implementation, there was provision of mobile internet for electronic transfer of the
positive DNA-PCR EID test results. There was no significant difference in turnaround time
based on health facility level.
The limitations of this study included the fact that it was a retrospective cohort descriptive
study. The use of existing medical records with incomplete information made data collection
challenging.
Interventions to improve the delays have potential multiple benefits, which include
improvement in the uptake of pediatric care and treatment for infants identified as infected,
and ultimately contribute to reducing HIV morbidity and mortality in children. In addition,
early knowledge of child’s status may serve a psychological boost for the mother to maintain
maternal adherence to ART leading to better maternal health and adherence to required health
care visits for HIV-uninfected children.
Conclusion
In conclusion, the central laboratory and district laboratory were major contributors to the
delays in TAT of initial EID in Lesotho. All geographical regions (highlands, foothills, and
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lowlands) and hospitals, and health centers were affected in a similar way. As technologies
evolve with the advent of point-of-care testing (POCT) EID assays becoming available, it will
be essential to evaluate how the new POCT approach impacts on the EID cascade. Further-
more, countries with similar challenges should consider efforts to improve timely initiation of
ART for HIV-infected children and delivery of negative results to caregivers or providers.
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Lifelong antiretroviral therapy (ART) reduces mother-to-child HIV transmission (MTCT) and
improves maternal health. Data on the outcomes of HIV-exposed infants (HEI) compared to
their unexposed counterparts in the era of universal ART is limited. We compared birth and
6-week outcomes among infants born to HIV-positive and HIV-negative women in Lesotho.
Methods
941 HIV-negative and 653 HIV-positive pregnant women were enrolled in an observational
cohort to evaluate the effectiveness of prevention of mother-to-child HIV transmission
(PMTCT) program after implementation of universal maternal ART in 14 health facilities.
Pregnancy, delivery, birth, and 6-week data were collected through participant interviews
and medical record review. DNA PCR testing for HEI was conducted within 2 weeks of birth
and at around 6 weeks of age. Data were analysed to estimate the distribution of birth out-
comes, mortality, HIV transmission and HIV-free survival at 6 weeks.
Results
HIV-positive women were older (mean age of 28.7 vs. 24.4 years) and presented for antena-
tal care earlier (mean gestational age of 23.0 weeks vs 25.3 weeks) than HIV-negative
women. Prematurity was more frequent among HEI, 7.8% vs. 3.6%. There was no differ-
ence in rates of congenital anomalies between HEI (1.0%) and HIV-unexposed infants
(HUI) (0.6%). Cumulative HIV transmission was 0.9% (N = 4/431) (95% CI:0.25–2.36) at
birth and 1.0% (N = 6/583) (95% CI:0.38–2.23) at 6 weeks. Overall mortality, including
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stillbirths, was 5.2% and 6.0% by 6 weeks for HUI and HEI respectively. Among liveborn
infants, 6-week HIV-free survival for HEI was 95.6% (95% CI:93.7–97.1) compared to
96.8% (95% CI:95.4–97.9) survival for HUI.
Conclusions
Implementation of universal maternal ART lowers MTCT at 6 weeks of age with no differ-
ences in congenital anomalies or early mortality between HIV exposed Infants and HIV
unexposed infants. However, HIV exposed infants continue to have high rates of prematurity
despite improved maternal health on ART.
Introduction
Effective prevention of mother to child transmission (PMTCT) programs offering universal
life-long antiretroviral therapy (ART) reduce HIV transmission to children from their mother
and improve maternal health [1,2]. A critical question remains as to whether the reduction in
MTCT rates and improvement in maternal health are coupled with improvement in birth out-
comes and survival among HIV-exposed infants (HEI) to match those of HIV-unexposed
infants (HUI).
There have been conflicting data reported on birth outcomes among HIV-positive women
who are on lifelong ART compared to HIV negative women. Some studies found that adverse
birth outcomes, such as increased preterm deliveries, stillbirths and low birth weight, occurred
more frequently among HEI [3–8]. Other studies found no association between use of ART
and adverse birth outcomes [9,10].
Intrauterine and perinatal HIV transmission measurement in the era of lifelong ART is lim-
ited. In Rwanda, a study measuring HIV-free survival in a cohort of HEI, found a 6-week
Mother to child transmission rate of 0.5% (95% CI:0.2–1.6) demonstrating the effectiveness of
lifelong ART for HIV-positive pregnant women in preventing perinatal HIV transmission
[11]. UNAIDS spectrum data in Lesotho reported an estimated 6-week transmission of 6.9%
in 2016 [1].
Lesotho is a mountainous country in southern Africa with one of the highest HIV preva-
lence documented in the world. The Lesotho Ministry of Health implemented universal ART
for all HIV-positive pregnant women in 2013 using a once-daily fixed dose combination of
tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFZ) [12,13]. HIV-
exposed infants are given nevirapine (NVP) for 6 weeks after birth.
The roll out of lifelong ART for all pregnant women in Lesotho provided a unique opportu-
nity to determine its effect on birth outcomes and survival of infants born to HIV-positive
mothers compared with a similar cohort of HIV-negative mothers and their HIV-unexposed
infants. The study also assessed the effectiveness of the Lesotho PMTCT program in reaching
the goal of the virtual elimination of new pediatric HIV infections in selected sites in Lesotho.
Methods
Design
HIV-positive and HIV-negative pregnant women attending routine antenatal care (ANC) ser-
vices were enrolled in a prospective observational cohort study from June 2014 to February
2016. Study personnel captured demographic, social, and medical information through
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participant interviews and extraction of medical record information during pregnancy, and at
delivery, birth and 6 weeks postpartum.
Setting
The study was conducted in 3 districts in Lesotho–Botha-Bothe, Thaba-Tseka and Mohale’s
Hoek. These districts were selected to include areas with varying levels of PMTCT service
delivery coverage, and heterogeneity in health-seeking behavior due to variances in terrain
(lowlands, foothills, mountains). We included all 5 hospitals in these districts and randomly
selected 9 medium volume (100–200 ANC women/year) or high (>200 ANC women/year)
health centers to be included in the study.
Population and enrollment
Eligible HIV-positive and HIV-negative pregnant women attending ANC in the study health
facilities were recruited for this study. They were eligible for study enrollment if they resided
in the area, planned to continue to receive services at the facility following delivery, were will-
ing to have their infant co-enrolled after birth, and were willing to provide written informed
consent. Population proportional sampling was used to estimate the enrollment target at each
of the 14 study facilities. The sample size for HIV-positive women was calculated based on a
4% estimated HIV transmission at 6–8 weeks in Lesotho at the time of study initiation with a
precision of 1.4% [12]. Consecutive consenting women were enrolled until the sample size was
reached. HIV-negative women were enrolled into an HIV seroincidence cohort study with
scheduled repeat HIV testing at 36 weeks gestation, delivery, and every 3–6 months postpar-
tum until 24 months postpartum [14].
Data collection
Study data were collected by trained study nurses through structured interviews and by
abstraction of data from clinical and laboratory records. Mother-infant pair information such
as demographic variables, date of last menstrual cycle, HIV status of spouse, disclosure of HIV
status was collected through structured interviews with the pregnant women. General health
and clinical history, ARV use and toxicity, adherence, retention in care, family planning, infant
feeding practices and infant growth were extracted from the women medical charts and clinic
registers. Electronic tablets were used to enter data directly into a web-based database
(SurveyCTO).
Gestational age at birth was estimated by the time between the date of last menstrual period
given by the women at first ANC and the date of birth. Very preterm birth was defined as
infant born at a gestational age of 28–32 weeks while preterm birth was infant born after 32
weeks but before 37 weeks [15]. In addition, miscarriage was defined as loss of pregnancy
before the gestational age of 28 weeks and stillbirth was considered when the pregnancy was
lost after 28 weeks [16].
Laboratory methods
Blood samples were collected from a subset of HEI at or within 2 weeks of birth and from all
HEI at 6–8 weeks of age to determine their HIV infection status. Trained nurses obtained
blood from infants by heel prick, which was spotted directly onto filter paper to create a dried
blood spot for HIV DNA PCR testing as per the standard Ministry of Health (MOH) protocol.
HIV testing was performed by the national reference laboratory using the Roche COBAS
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Ampliprep/COBAS TaqMan HIV-1 qualitative test (v2.0). Test results were obtained directly
from the laboratory and entered into the study database.
Statistical analysis
Quantitative data analysis was performed using STATA version 15.1 (College Station, TX,
USA). We summarized categorical variables using frequencies and percentages of participants
and continuous variables using means (+/- standard deviation). Maternal baseline characteris-
tics were stratified by HIV status at enrollment. We compared birth outcomes between HIV-
exposed and HIV-unexposed infants. HIV-free survival was estimated as the proportion of
children alive and HIV-negative among all exposed children. The precision around survival
estimates was assessed by 95% confidence intervals. We used the Kaplan Meier curves to
graphically display infant mortality, infection, and HIV free survival. We performed complete
case analysis, and missing data were not imputed.
Ethical considerations
The study was approved by the Lesotho Ministry of Health Research and Ethics Committee,
the Baylor College of Medicine Children’s Foundation Lesotho Institutional Review Board
(IRB), and the George Washington University Committee on Human Research IRB. All
women were informed of the study protocol, requirements, and risks and benefits, and pro-
vided written informed consent to participate in the study.
Results
Participant characteristics
A total of 1594 pregnant women (941 HIV-negative and 653 HIV-positive) were enrolled in
the study with their infants (Fig 1). Eight HIV negative women seroconverted before delivery.
Delivery information was available for 95.4% of HIV positive women (623/653 and 92.2% of
HIV negative women (868/941). 623 HIV positive women gave birth to 631 HIV exposed
infants (HEI) and 868 HIV negative women gave birth to 879 HIV unexposed infants (HUI).
Six week-follow-up information was available for 577 and 831 HEI and HUI respectively.
Characteristics of HIV-positive and HIV-negative study women at enrollment are pre-
sented in Table 1. HIV-positive pregnant women were older than their HIV-negative counter-
parts with a mean age of 28.7 (+/- 5.5) compared to 24.4 (+/- 5.7) years. HIV-positive women
also presented earlier for ANC at a mean gestational age of 23.0 (+/- 8.7) weeks compared to
25.3 (+/- 8.2) weeks. Overall, 83.5% of the women were married, and 59.3% had disclosed their
HIV-status to their partner/husband. Concerning HIV status of spouses, 4.2% of HIV negative
women had HIV positive partners while 29.6% of HIV positive women had an HIV negative
partner.
Among HIV-positive women, 97.8% were receiving ART at enrollment with 84.2% receiv-
ing the TDF/3TC/EFV first-line regimen. Among the 619 women with data available on the
timing of ART, 249 (40.2%) initiated ART before conception and 370 (59.8%) initiated ART
after conception.
Birth outcomes
Overall, 91.6% of study women delivered in a health facility and 96.8% (n = 1443) of infants
were born alive (Table 2). There was no difference in the proportion of infant stillbirths, how-
ever, HIV-positive women were more likely to have had a macerated stillbirth (consistent with
antepartum death), while HIV-negative women were more likely to have had an intrapartum
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death (fresh stillbirth or a liveborn infant who died within two hours of delivery). The risk of
premature birth in HEI was more than double the risk of prematurity in HUI (7.8% vs 3.6%).
The risk of very premature births (<32 weeks gestational age) was also substantially higher in
HEI (2.2%) compared to HUI (0.4%).
Of the 249 women who initiated ART pre-conception, 24 (9.6%) had premature babies
compared to 27 (7.3%) among the 370 women who initiated ART post-conception. The rates
of very low weight (<1.5kgs) and low birth weight (<2.5 kgs) among women who initiated
ART before conception were 1.7% and 11.6% respectively compared to 1.2% and 11.9%
among women who initiated ART after conception.
Fig 1. Study enrollment for comparison of 6-week PMTCT outcomes for HEI and HUI in the era of lifelong ART.
https://doi.org/10.1371/journal.pone.0226339.g001
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The rate of congenital anomalies was 0.6% and 1% among HEI and HUI respectively.
Infant survival
There were no substantial differences in the rates of infant survival at 6 weeks of age by infant
HIV exposure status (Fig 2 and Table 3). When including all deaths (liveborn plus stillbirths),
the estimated survival rates were 94.8% (95% CI: 93.1–96.1) among HUI and 94.0% (95% CI:
91.8–95.7) among HEI. Analysis of postnatal deaths only (excluding stillbirths), yielded esti-
mated survival rates of 96.8% (95% CI: 95.4–97.9) and 96.7% (95% CI: 95.0–98.0) for HUI and
HEI respectively. Adjusting for maternal mortality and gestational age at first ANC visit, infant
HIV exposure status was not associated with early infant mortality (aOR = 1.06, 95% CI: 0.56–
1.99).
Mortality and HIV-free survival among HEI
Six infants were diagnosed with HIV infection by 6 weeks of age, including 4 diagnosed at
birth, and 2 diagnosed at 6 weeks of age (Table 4). The estimated HIV transmission rate
among those tested at birth was 0.9% (95% CI: 0.25–2.36) and by 6 weeks the overall HIV
transmission was 1.0% (95%CI: 0.38–2.23). The estimated HIV-free survival including still-
births was 92.8% (95% CI: 90.5–94.8), and 95.6% (95% CI: 93.7–97.1) when stillbirths were
excluded.
Table 1. Characteristics of study women at enrollment.
Maternal HIV Status Total Mothers
HIV-negative (N = 941) HIV-positive (N = 653�) Total (N = 1593)
n (%) n (%) n (%)
Maternal age in years (mean +/- SD) 24.4 +/- 5.7 28.7 +/- 5.5 26.0 +/- 6
Gestational age at first ANC in weeks (mean, SD) 25.3 +/- 8.2 23.0 +/- 8.7 24.4 +/- 8.5
Marital Status: Married 801 (85.1) 528 (81.0) 1329 (83.4)
Mother disclosed HIV status to husband/partner 521 (55.4) 422 (64.9) 943 (59.3)
Missing Data 0 3 3
Maternal ARV Regimen at enrollment
TDF+3TC+EFV N/A 548 (84.2) 548 (84.2)
TDF+3TC+NVP N/A 25 (3.8) 25 (3.8)
AZT+3TC+EFV N/A 28 (4.3) 28 (4.3)
AZT+3TC+NVP N/A 29 (4.5) 29 (4.5)
ART-other regimens N/A 7 (1.1) 7 (1.1)
None N/A 14 (2.2) 14 (2.2)
Missing data N/A 1 1
Husband/Partner’s HIV Status
Positive 19 (4.2) 230 (68.9) 249 (31.8)
Negative 422 (94.0) 99 (29.6) 521 (66.5)
Unknown 8 (1.8) 5 (1.5) 13 (1.7)
Not tested 492 318 810
Husband/Partner Taking ARVs
Yes 14 (73.7) 166 (72.2) 180 (72.3)
No 5 (26.3) 63 (27.4) 68 (27.3)
Unknown 0 1 (0.6) 1 (0.4)
�One woman was enrolled but excluded from analysis due to missing enrolment questionnaire data
https://doi.org/10.1371/journal.pone.0226339.t001
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Five of the 6 HIV-infected infants had mothers that were initiated on ART post-conception
(Table 5). Five of the mothers of infected infants had records of viral load at delivery and of
these, 4 women had viral loads above 100,000 copies/ml. All mothers were on a TDF/3TC/EFZ
regimen as per the national guidelines.
At 6 weeks, the mortality rate was higher among premature babies 24.6% (17/69) compared
to mature infants 2.1% (29/1391). There was also a difference in 6-8-week mortality between
low birth weight infants compared to normal birth weight infants (7.0% vs. 1.9%). Very low
birth weight infants had higher risk of death within 6–8 weeks compared to infants born
weighing at least 1.5kgs or more (30% vs 2.2%).
Discussion
This is the first prospective cohort study in Lesotho comparing birth and 6-week outcomes
between HEI and HUI in a large cohort of HIV-positive and negative women and their infants.
We found that birth outcomes of HEI were similar to those of HUI except for the frequency of
prematurity, which was found to be significantly higher among HEI. While prematurity
among HEI has been reported in several other studies [17–19], there have been few studies
Table 2. Birth outcomes by mother’s HIV status at delivery.










Miscarriage� 7 (0.8) 10 (1.6) 17 (1.1) 0.16
Mode of Delivery
Vaginal 748 (86.6) 525 (84.8) 1273(85.9) 0.11
Cesarean section 116 (13.4) 94 (15.2) 210(14.1)
Place of delivery
Health facility 786/858 (91.6) 560/620(90.3) 1346(91.1)
Home 67 (7.8) 53 (8.5) 120 (8.1)
Other 5 (0.5) 7 (1.1) 12 (0.8)
Missing data 10 2 12
Birth Outcome
Liveborn† 840 (96.8) 603 (96.8) 1443 (96.8)
Antepartum death 5 (0.6) 12 (1.9) 17 (1.1) 0.01
Intrapartum death 23 (2.6) 8 (1.3) 31 (2.1)
Newborn Maturity
Mature 835 (96.0) 574 (91.7) 1409 (94.2) 0.001
Premature 35 (4.0) 52 (8.3) 87 (4.8)
Very Premature delivery (<32 wks) 3 (0.4) 13 (2.2) 16 (1.1) 0.001
Premature delivery (<37 wks) 31 (3.6) 48 (7.8) 79 (1.6) <0.01
Missing data 5 1 6
Newborn with congenital anomalies 9 (1.0) 4 (0.6) 13 (0.9 0.56
Birth Weight in kilograms
Normal weight 736 (90.8) 514(88.3) 1250(89.7) 0.15
Low Birth Weight (<2.5 kg) 75 (9.2) 68(11.7) 143(10.3)
Very Low Birth Weight (<1.5 kg) 7 (0.9) 8 (1.4) 15(1.1) 0.43
�There were no miscarriages or stillbirths recorded among the 8 women who seroconverted between enrollment and delivery
†This does not include babies who were born alive and died with two hours.
https://doi.org/10.1371/journal.pone.0226339.t002
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conducted within routine health systems with large numbers of both HIV-positive and HIV-
negative women in the era of lifelong ART for all pregnant women with TDF-based ART regi-
mens. In our study, infant prematurity and low birth weight were not significantly different
among women who initiated ART before conception compared to those who initiated ART
after conception. This is consistent with other studies that reported no relationship between
preconception ART and preterm delivery [17,18]. However, in a systematic review and meta-
analysis of adverse pregnancy outcomes and timing of initiation of ART, Uthman et. al
reported significantly higher risk of prematurity among HEI whose mothers initiated ART
before conception compared to those who initiated ART after conception (pooled RR 1.20,
95%CI 1.01–1.44) [8].
As recommended for first-line treatment in Lesotho, 88% of HIV-positive women were on
TDF-based ART regimens. In a systematic review and meta-analysis looking at safety of TDF-
based regimens in pregnancy for HIV-positive women and their infants, the rates of prematu-
rity and stillbirths were significantly lower among women on TDF-based ART compared to
other ART regimens [20, 21]. However, even with the use of TDF regimens, our study showed
that HEI still had a higher risk of prematurity compared to HUI.
We found that HEI were more likely to die antepartum (1.9% versus 0.6%), consistent with
medical complications, while HUI were more likely to die during the intrapartum period
(2.6% versus 1.3%), consistent with obstetrical complications. However, it may be important
to note that these women were followed up only from their first ANC and we may have missed
some of the antepartum deaths which occurred before women were enrolled in the study. A
number of studies have explored causes of antepartum death among HEI. In South Africa and
Botswana, maternal vascular malperfusion was more frequent among HIV-positive women
Fig 2. Survival of HUI and HEI at six weeks of age including and excluding stillbirths.
https://doi.org/10.1371/journal.pone.0226339.g002










Including stillbirths 46/877 (5.2%) 94.8% [93.1–96.1] 38/631 (6.0%) 94.0% [91.8–95.7]
Excluding stillbirths 27/858 (3.2%) 96.8% [95.4–97.9] 20/613 (3.3%) 96.7% [95.0–98.0]
https://doi.org/10.1371/journal.pone.0226339.t003
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and placenta insufficiency associated with hypertension accounted for most stillbirths [22,23].
In our study, postpartum infant mortality at 6 to 8 weeks was independently associated with
gestational age, but not with HIV exposure status.
We found one of the lowest 6-week HIV transmission rates (1.0%) reported in Lesotho cou-
pled with very high HIV-free survival among liveborn infants at 6 weeks of age. This is a signif-
icant improvement compared to the estimated 6-week transmission of 7% reported in Lesotho
in 2016 and in other countries in the region [1, 24]. Two-thirds of the HIV-positive infants
identified were infected in utero. Most women presented for their first ANC visit toward the
end of the second trimester, contrary to the WHO recommendation for women to present
during the first trimester. Early ANC visits are especially important for HIV-positive pregnant
women because earlier ART initiation may further reduce MTCT in utero [12,25]. This was
buttressed by the findings that almost all women who transmitted HIV to their infants had a
high viral load despite being on ART. Therefore, we agree with Smith et. al that it is essential to
maximize viral suppression for HIV-positive women on ART [25].
Our findings indicate that the current universal ART program within the setting of routine
care is effective. Implementation of this program showed that high ANC utilization, and high
uptake of ART during pregnancy, including a high proportion of facility-based deliveries, col-
lectively led to improved pregnancy outcomes among HIV-positive women. Our study also
demonstrates the importance of incorporating implementation research to document program
effectiveness within routine, public health settings. Lesotho’s experience shows that when
PMTCT programs are well implemented, routine program setting can achieve high effective-
ness, comparable to more controlled research settings.
A limitation of our study is that it measured birth outcomes and 6-week HIV-free survival
in a facility-based population and may have missed women and children who did not seek
care in health facilities. We may have also missed women who lost pregnancies early. In addi-
tion, our study may have potential systematic errors arising from estimation of gestational age
with the potential of misclassifying baby’s maturing at delivery. However, since ANC atten-
dance in Lesotho is higher than in many African countries, we believe that the results are










Including stillbirths 38/627 (6.1%) 6/581 (1.0%) 44/613 (7.2%) 92.8% [90.4–94.7]
Excluding stillbirths 20/609(3.3%) 6/581 (1.0%) 26/595(4.4%) 95.6% [93.7–97.1]
https://doi.org/10.1371/journal.pone.0226339.t004
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before delivery (months)
Infant maturity and






1 23 32 Pre-conception 32.5 Mature—2.4 TLE 36,881
2 22 24 Post-conception 3.5 Mature—3.5 TLE 109,000
3 32 18 Post-conception 5.6 Mature—3.5 TLE 428,054
4 18 18 Post-conception 4.6 Mature—2.8 TLE 320,000
5 23 10 Post-conception 6.9 Mature—2.8 TLE 100,062
6 25 29 Post-conception 2.6 Mature—2.9 TLE -
+All mothers were initiated on Tenofovir-Lamivudine-Efavirenz (TLE) after HIV diagnosis and remained on this regimen throughout the study.
https://doi.org/10.1371/journal.pone.0226339.t005
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reflective of the Lesotho context [26, 27]. The successful reduction of perinatal HIV transmis-
sion that we report may not be comparable in areas with lower ANC attendance and low rates
of facility-based deliveries. Additionally, study sites were purposively selected so the findings
may not be generalizable to the whole country of Lesotho, especially to low volume facilities,
which were not included in the study. However, the purposive selection of sites from the three
geo-ecological settings in Lesotho (highlands, foothills, lowlands) does account for the vari-
ances in health-seeking behaviors.
Conclusion
Implementation of universal maternal ART was associated with low MTCT among infants at 6
weeks of age with no differences in congenital anomalies or early mortality between HEI and
HUI. However, HEI continue to have increased rates of prematurity even in the era of lifelong
combination ART.
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Population-based HIV-free survival at 18-24 months of age among HIV-exposed infants 21 
in high prevalence settings in the era of treatment for all is largely unknown. We 22 
conducted a community-based survey to determine outcomes of HIV-exposed infants at 23 
18-24 months in Lesotho. 24 
Methods 25 
Between November 2015 and December 2016, we conducted a survey among 26 
households with a child born 18-24 months prior to data collection. Catchment areas 27 
from 25 health facilities in Butha-Buthe, Maseru, Mohale’s Hoek and Thaba-Tseka 28 
districts were randomly selected using probability proportional to size sampling. 29 
Consecutive households were visited and eligible consenting caregivers and children 30 
were enrolled. 31 
Rapid HIV antibody testing was performed on mothers of unknown HIV status (never 32 
tested or tested HIV-negative >3 months prior) and their children, and to children born to 33 
known HIV-positive mothers.  Information on demographics, health-seeking behavior, 34 
HIV, and mortality were captured for mothers and children, including those who died. 35 
The difference in survival between subgroups was determined using the log-rank test.  36 
Results 37 
Of the 1,852 mothers/caregivers enrolled, 570 mothers were HIV-positive. The mother-38 
to-child HIV transmission rate was 5.7% [95% CI: 4.0-8.0]. The mortality rate was 2.6% 39 
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among HIV-unexposed children.  HIV-free survival was 91.8% [95% CI: 89.2-93.8] 41 
among HIV-exposed infants. Disclosure of mother’s HIV status (aOR = 4.9, 95% CI: 1.3-42 
18.2) and initiation of cotrimoxazole prophylaxis in the child (aOR = 3.9, 95% CI: 1.2-43 
12.6) were independently associated with increased HIV-free survival while child growth 44 
problems (aOR = 0.2, 95% CI: 0.09 – 0.5) were independently associated with reduced 45 
HIV-free survival. 46 
Conclusion 47 
Even in the context of lifelong antiretroviral therapy among pregnant and breastfeeding 48 
women, HIV has a significant effect on survival among HIV-exposed children compared 49 
to unexposed children.  Lesotho has not reached elimination of HIV transmission from 50 
mother to child.  51 
 52 
Introduction 53 
HIV-free survival is the gold standard in measuring the effectiveness of 54 
prevention of mother-to-child HIV transmission (PMTCT) programs especially among 55 
breastfeeding populations [1,2].  56 
Since 2010, new HIV infections among children have declined by 35%, from 57 
270,000 [170,000–400,000] in 2010 to 160,000 [110,000–260,000] in 2018, 58 
demonstrating a nearly 64% decline since 2001when almost half a million of children 59 
were newly infected with HIV [3]. Most of the infections among children remain 60 
attributable to mother-to-child transmission (MTCT) [4,5]. Program data are now starting 61 
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using real world data which strengthen global reports that use modelling data [2,6-8]. 63 
Most of these studies report HIV-free survival before lifelong antiretroviral therapy (ART) 64 
was rolled out. 65 
With an estimated HIV prevalence of 25.6%, Lesotho has the second-highest 66 
national HIV prevalence worldwide [9,10]. Among antenatal care (ANC) attendees, HIV 67 
prevalence ranges from 5.4% among adolescents aged 15-19 years, to 21.5% among 68 
women aged 20-24 years, 37.5% among those aged 25-29 years, and 40% among 69 
those aged 30-39 years [11].  70 
Lesotho’s national guidelines recommend that opt-out HIV testing be offered to all 71 
pregnant women presenting to ANC clinic or in labor with unknown HIV status. If HIV-72 
negative, women should be retested for HIV at 36 weeks gestation if the prior test was 73 
performed ≥ 6 weeks earlier, or if not done prior to delivery, then HIV testing should be 74 
done during labor and delivery [12]. HIV deoxyribonucleic acid polymerase chain 75 
reaction (DNA-PCR) or total nucleic acid (TNA) testing is recommended for infants 76 
younger than nine months of age in Lesotho. Infants with a positive HIV DNA-PCR or 77 
TNA test result are initiated on ART immediately while awaiting results of the repeat 78 
confirmatory DNA-PCR test. Final documentation of the child’s HIV status is conducted 79 
six weeks following cessation of breastfeeding using HIV DNA-PCR testing among 80 
infants younger than nine months of age, or HIV rapid testing, with DNA-PCR if the 81 
rapid test is positive, among infants and children older than nine months of age [12].  82 
Traditionally, MTCT rates are assessed at health facility level and focused on six-83 
week MTCT, though in breastfeeding populations, children are exposed to HIV through 84 
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estimates are potentially biased because they exclude women and children who do not 86 
utilize health facilities especially in populations where formal health care utilization rates 87 
are low. Community-based studies to estimate HIV-free survival among HIV-exposed 88 
children overcome some bias concerns in facility-based studies. However, since 2013, 89 
when the Lesotho Ministry of Health (MOH) adopted the World Health Organization 90 
PMTCT guidelines on universal treatment [8], no community-based assessment of HIV-91 
free survival has been undertaken in Lesotho. The Lesotho population-based impact 92 
assessment survey found an overall MTCT rate of 2.8% [14,15]. We carried out a 93 
community household survey to estimate the HIV-free survival of HIV-exposed children 94 
18-24 months of age after the introduction of lifelong ART. 95 
Materials and methods 96 
Study design 97 
Between November 2015 and December 2016, we conducted a cross-sectional, 98 
community-based survey among households with children born in the previous 18-24 99 
months to estimate MTCT rates, mortality, HIV prevalence, and HIV-free survival among 100 
children.   101 
Sampling procedures 102 
Four districts were purposively selected for the study: Butha-Buthe, Maseru, 103 
Mohale’s Hoek, and Thaba Tseka. The first three districts represent the three national 104 
ecological zones: highlands, foothills and lowlands. The ecological zones account for 105 
variation in overall PMTCT service delivery coverage and heterogeneity in health-106 
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district in the country. The selection of these districts was expected to make the 108 
sampling nationally representative. Of the 78 facilities across the four districts, 16 were 109 
excluded from the sampling frame, including facilities that were determined to be difficult 110 
to reach (e.g., typically only accessible by helicopter). Within each district, we used a 111 
multi-stage sampling approach to obtain a representative sample of HIV-positive and 112 
HIV-negative mothers and children.  First, health facilities from each study district were 113 
randomly selected using probability proportional to size sampling based on the annual 114 
number of live births. Ten facilities from Maseru District and five facilities each from the 115 
other three districts were randomly selected, for a total of 25 facilities. Communities 116 
were defined as the villages within the catchment area of a health facility. In each 117 
catchment area, all villages were assigned a number and then random selection was 118 
used to indicate the village from which recruitment would begin. Recruitment continued 119 
according to a pre-determined direction in the next closest village until the approximated 120 
sample size target was obtained. Study teams recruited participants from all households 121 
meeting the inclusion criteria within a village. If the study team reached approximately 122 
half of the target for that catchment area in one village, the team then stopped 123 
recruitment and moved to the next village to ensure at least two villages were captured 124 
for each catchment area. 125 
To determine the sample size per facility catchment area, we estimated the 126 
expected number of HIV-infected women who had given birth in each area 127 
proportionate to the catchment population size. To identify eligible households within the 128 
catchment area, we went door-to-door or engaged community health workers to identify 129 
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collection. If the mother or a primary caregiver was not available to complete the survey, 131 
a return appointment was made.  132 
Recruitment and enrollment of study population 133 
The study population included mothers and children who were born 18-24 134 
months prior to the data collection time. Household visits were made by trained 135 
research assistants responsible for consenting and data collection, and HIV counselors 136 
responsible for HIV testing. All eligible households were included in the study if the 137 
primary caregiver was willing to provide verbal informed consent. Households were 138 
eligible for study participation, regardless of the vital status of the child (alive/deceased). 139 
Households were excluded if members of household were not willing to participate, or if 140 
the primary caregiver was less than 18 years and was not the father or mother of the 141 
child. Households were visited consecutively, informed about the study, and caregivers 142 
were invited to participate in the study. If the mother was deceased or was not currently 143 
living in the household, consent for study participation was obtained from the child’s 144 
primary caregiver.  145 
Data collection 146 
Caregivers or parents were interviewed in Sesotho or English by research 147 
assistants using a structured data collection tool with responses captured electronically. 148 
The questionnaire was developed specifically for the purpose of this study and collected 149 
data needed to answer study questions. Research assistants first determined the child’s 150 
HIV exposure status and then administered the questionnaire to the mother or 151 
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health facilities for HIV and maternal and child health services, maternal HIV status, 153 
maternal and infant receipt and use of antiretroviral drugs during pregnancy and after 154 
delivery (if known HIV-positive), infant feeding practices, and general well-being, 155 
including growth and development. The child health card and/or maternal health card 156 
were used to confirm caregiver information.  Mortality information for mothers and 157 
children who died was also captured, and attempts were made to determine HIV status 158 
prior to death.  159 
Biologic measurements 160 
During household visits, blood was collected through finger stick from study 161 
participants by a trained community counselor for HIV rapid antibody testing according 162 
to the national HIV program testing algorithm. The first test performed was the 163 
Determine™ HIV-1/2 (manufactured by Alere). Participants with a negative Determine™ 164 
assay were told their HIV negative status. All participants who tested positive underwent 165 
a second test (with a new finger prick sample) using Uni-Gold™ Recombigen® HIV-1/2 166 
and were told their HIV positive status if the second test was also positive. All maternal 167 
participants had a DBS sample taken to be stored in the laboratory for quality control. In 168 
addition, DNA-PCR testing was performed on the DBS sample for all maternal 169 
participants to confirm the status recorded from the field. Further, DBS specimens were 170 
collected from all enrolled children for HIV DNA-PCR confirmatory testing regardless of 171 
rapid test results.  172 
All tests conducted for this study were recorded in a log at the testing laboratory 173 
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obtained directly from the laboratory and entered into the study database to link 175 
questionnaire responses with laboratory results. Study data collectors and investigators 176 
reviewed laboratory results and identified discordant or confirmatory results that 177 
required follow-up by the HIV counselors.  178 
Sample size calculation and Data analysis  179 
Based on previous PMTCT evaluation studies in Rwanda and Malawi, we 180 
expected HIV-free survival among 18-24-month-old HIV-exposed infants would be lower 181 
than the estimate from Rwanda (91.1%) due to less extensive PMTCT coverage in 182 
Lesotho in comparison to Rwanda [16]. Assuming HIV-free survival in Lesotho was 183 
about 85%, we needed 545 HIV-exposed infants to estimate HIV-free survival with 3% 184 
precision. Adjusting the sample size by 10% for miscellaneous events (e.g., missing 185 
data, consent to some but not all study activities) we targeted to enroll 600 HIV-exposed 186 
infants.  Given the HIV prevalence of approximately 25.4% among pregnant women in 187 
ANC, we would need to visit or approach 2,363 households with children in the 18-24-188 
month age range to identify 600 HIV-exposed infants. To account for potentially 15% 189 
refusal rate to participate in the study and interviews with non-maternal caregivers of 190 
HIV-exposed children (who may not be able to adequately answer questions needed to 191 
address the research aims) we needed to visit approximately 2,700 households to reach 192 
the required sample of HIV-exposed infants and their mothers.  193 
We summarized categorical variables using frequencies and percentages. 194 
Continuous variables were summarized using means and standard deviations, or 195 
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proportion of children alive and HIV negative among all HIV-exposed children. The 197 
precision around survival estimates was summarized using 95% confidence intervals. 198 
We used the log-rank test to determine whether there were differences in HIV-free 199 
survival between subgroups. Comparisons included HIV-infected versus HIV-exposed 200 
but uninfected children; and HIV-exposed versus HIV-unexposed children. Type I error 201 
rate (α) for statistical tests was set at 0.05. We performed complete case analysis, and 202 
missing data were not imputed. 203 
We used multivariate logistic regression models to test the independent 204 
association of ANC attendance, mode and place of delivery, gestational age at birth, 205 
birth weight, maternal vital status, adherence to and timing of initiation of antiretroviral 206 
drugs, infant feeding method and nutritional status with HIV-free survival among HIV-207 
exposed children. All statistical data analysis was performed using STATA version 14.2 208 
(Stata Corp). 209 
Ethical considerations 210 
The study was approved by the Lesotho MOH Research and Ethics Committee 211 
and the George Washington University’s Office of Human Research. All participants 212 
were informed of the study objectives, were given the opportunity to ask questions and 213 
provided verbal informed consent to participate in the study.  214 
Once a household was determined to meet the eligibility criteria, the mother/caregiver of 215 
the eligible child was identified and informed about the evaluation. The verbal informed 216 
consent text included statements that described the purpose of the evaluation, the 217 
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statement for mothers/caregivers to provide consent for themselves and their children (if 219 
applicable). The interviewer read each of these statements in the participants’ language 220 
of choice (English or Sesotho) exactly as written and documented the response on an 221 
electronic device used for data collection with a password verification process.  The 222 
mother/caregiver had the opportunity to ask questions regarding enrollment into the 223 
evaluation.  The consent process was structured so that a participant could agree to 224 
participate in some activities, but not others. Biological mothers were the preferred 225 
participants, but if the mother was deceased or not currently living in the household, 226 
consent was obtained from the child’s primary caregiver, who was asked to respond to 227 
questions to the extent possible.  228 
Results 229 
Between November 2015 and December 2016, we screened 11,169 households 230 
for the study eligibility (Fig 1). Of the 2,190 eligible households, 1,852 231 
mothers/caregivers consented and were enrolled in the study. Of the 338 households 232 
that declined to participate, the following reasons were provided: caregiver, child or both 233 
were unavailable (n=178), (157 of whom were at work); lack of time to participate 234 
(n=71); no incentive provided (n=25); not comfortable to participate (n=16); caregiver 235 
did not feel they had enough information to answer questions (n=15); mother needed 236 
husband’s permission (n=9); caregiver was below 18 years of age (n=6); and other 237 
reasons (n=18).From the enrolled households, there were 1,884 deliveries (including 66 238 
twin births) that occurred 18-24 months prior to data collection. Most of the children 239 
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(30.7%) of biological mothers reported and knew their HIV-positive status. Thirty-nine 241 
mothers were newly diagnosed HIV-positive during the study, of whom 38 had 242 
previously tested HIV-negative during the index pregnancy. A total of 1,199 (64.7%) 243 
biological mothers were HIV-negative and 83 mothers were of unknown HIV status and 244 
unavailable for testing 245 
Fig 1. Participants Screening, Enrollment, and Outcomes 246 
 247 
 248 
Characteristics of caregivers  249 
The mean age (±SD) of mothers was 27.8 ± 6.1 years (Table 1). Overall, 95.8% 250 
of mothers attended ANC at least once with over 80% of women delivering in health 251 
facilities. One-fifth (20.8%) of mothers presented with known HIV status at ANC. Most 252 
HIV-positive mothers (94.7%) disclosed their HIV status with 59.9% disclosing it to their 253 
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Mean Age (SD) 26.7 (5.9) 30.1 (6.0) 27.7 (5.2) 27.8 (6.1) 
Attended ANC during pregnancy 1152 (96.4) 530 (94.8) 56 (93.3) 1738 (95.8) 
Mean gestational age in weeks at first ANC (SD) 16.7 (7.5) 16.6 (7.9) 14.7 (8.1) 16.7 (7.6) 
Attended 4+ ANC visits 710 (70.6) 302 (68.8) 7 (53.8) 1019 (70.0) 
Child delivered at a health facility 934 (81.1) 416 (78.5) 45 (83.3) 1395 (80.4) 
Mother known HIV-positive during pregnancy  - 114 (20.8) - 114 (6.6) 
Mother tested for HIV during pregnancy 1161 (98.1) 418 (73.3) 8 (80.0) 1587 (85.7) 
Mother disclosed HIV status to anyone 918 (79.7) 514 (94.7) - 1432 (84.3) 
Mother disclosed HIV status to spouse/partner 706 (76.9) 308 (59.9) - 1014 (70.8) 
Mother disclosed HIV status to other family 
members 
362 (39.4) 373 (72.6) - 735 (51.3) 
Mother disclosed HIV status to others 4 (0.4) 26 (5.1) - 49 (3.4) 
 264 
Characteristics of children 265 
The child participants included 64 twins (3.4%) and 52.5% of the children were male 266 
(Table 2). Preterm births occurred in 9.1% of children, with HIV-exposed children 267 
slightly more likely to have a preterm birth. Overall, 95.2% of infants were ever 268 
breastfed, with a breastfeeding rate of 90.7% among HIV-exposed infants. The mean 269 
(SD) birth weight was 3.0 (0.5) with HIV exposed infants having slightly lower mean 270 
birth weight compared to HIV unexposed infants.  HIV-unexposed infants were 271 
breastfed longer with a mean of 15 months compared to HIV-exposed infants, who were 272 



























Twin 34 (2.8) 30 (5.1) 0 (0) 64 (3.4) 
Male 609 (50.5) 324 (55.7) 56 (59.0) 989 (52.5) 
Stillbirth 4 (0.3) 2 (0.3) 2 (2.1) 8 (0.4) 
Preterm birth 106 (9.0) 54 (9.9) 3 (3.6) 163 (9.1) 
Mean birth weight (SD) 3.05 (0.5) 2.9 (0.6) 3.06 (0.4) 3.02 (0.5) 
Child ever breastfed 1169 (97.6) 519 (90.7) 81 (91.0) 1769 (95.2) 
Child still breastfeeding after 
18 months 
200 (17.1) 47 (9.1) 3 (3.7) 
250 (14.1) 
Median time child was 
breastfed (IQR) (months) 
15 (10 – 18) 11 (6 – 14) 12 (6 – 16) 12 (7 – 18) 
 279 
There were 37 reported child deaths, 16 of whom were from HIV-positive 280 
mothers. Thirty-three children were identified as HIV-positive within the participating 281 
households among whom 10 were newly diagnosed during the study. Of the ten 282 
children who were newly diagnosed with HIV, five had previously tested HIV-negative, 283 
three were from known HIV-positive mothers but had never been tested, and two were 284 
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Maternal use of antiretroviral therapy 288 
Overall, 86.8% of HIV-positive women used ART during pregnancy. Based on 289 
child HIV status, 87.4% and 71.4% of mothers of HIV-uninfected children and HIV-290 
infected children were enrolled on ART respectively (Table 3). Most mothers (89.1%) 291 
initiated ART either before or during pregnancy. Among mothers of HIV-infected 292 
children, 37.6% started ART either during or after breastfeeding period compared to 293 
9.6% of mothers of HIV-uninfected children. At the time of the study, 88.0% of HIV-294 
positive mothers reported currently taking ART. Among HIV-exposed children, 89.3% 295 
received nevirapine prophylaxis within three days of delivery. Of the 13 HIV-infected 296 
children who had records about their treatment initiation, 12 were initiated on ART. 297 
Table 3: Maternal Use of Antiretroviral Drugs During Pregnancy by Child’s HIV 298 















Mother had a CD4 test done when pregnant 282 (83.7) 12 (75.0) 294 (85.3) 
Missing 30 3 33 
Mother received ART during this pregnancy 285 (87.4) 10 (71.4) 295 (86.8) 
Missing 41 5 46 
Medicine received by mothers who took antiretroviral drugs during pregnancy* 
AZT 16 (5.7) 0 16 (5.5) 
ART for life 261 (92.9) 10 (100.0) 271 (93.1) 
Other 4 (1.4) 0 4 (1.4) 
Missing 4 0 4 
Time mothers started taking ART* 
Before pregnancy with this child 131 (39.5) 4 (25.0) 135 (38.8) 
During pregnancy with this child 169 (50.9) 6 (37.5) 175 (50.3) 
During breastfeeding of this child 20 (6.0) 5 (31.3) 25 (7.2) 
After breastfeeding of this child 12 (3.6) 1 (6.3) 13 (3.7) 
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Regimen taken by the mother during pregnancy† 
TDF+3TC+EFV 204 (80.3) 8 (80.0) 212 (80.3) 
TDF+3TC+NVP 16 (6.3) 2 (20.0) 18 (6.8) 
AZT+3TC+EFV 10 (3.9) 0 10 (3.8) 
AZT+3TC+NVP 21 (8.3) 0 21 (8.0) 
Other 3 (1.2) 0 3 (1.1) 
Missing 7 0 7 
Mother currently taking ART 313 (88.2) 16 (84.2) 329 (88.0) 
* Total N is among those who received antiretroviral drugs during pregnancy 300 
†Total N is among those who received ART for life 301 
 302 
 303 
Mortality, HIV transmission, and HIV-free survival among 304 
children 305 
Tables 4a and 4b summarize child outcomes by HIV exposure status.  The 306 
estimated child mortality was 2.6% (95% CI: 1.6- 4.2) among HIV-exposed children 307 
compared to 1.4% (95% CI: 0.9 – 2.3) among HIV-unexposed children.  The estimated 308 
HIV transmission was 5.7% (95% CI: 4.0-8.0). HIV-free survival was 91.8% (95% CI: 309 
89.2-93.8). The majority of child deaths occurred after the neonatal period (Table 4b). 310 










Child mortality 1.4 [0.9 – 2.3] 2.6 [1.6 – 4.2] 1.8 [1.3 – 2.5] 
HIV infection - 5.7 [4.0 – 8.0] - 
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Table 4b. Timing of Children’s Death by HIV Exposure (N=28) 316 













Day 0 4 (26.7) 0 2 (100) 6 (21.4) 
Within 24 hours 1 (6.7) 1 (9.1) 0 2 (7.2) 
Within 28 days 3 (20.0) 3 (27.3) 0 6 (21.4) 
More than 28 days 7 (46.6) 7 (63.6) 0 14 (50.0) 
 317 
Factors associated with HIV-free survival among children 318 
Table 5 summarizes factors associated with mortality, HIV transmission and HIV-319 
free survival among children. Disclosure of mother’s HIV status (aOR = 4.9, 95% CI: 320 
1.3-18.2) and initiation of cotrimoxazole prophylaxis in child (aOR = 3.9, 95% CI: 1.2-321 
12.6) were independently associated with increased HIV-free survival while child growth 322 
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Factors Associated with Infant Mortality 
Infant was a twin (ref=No) 7.1 [3.0-16.8] 0.00 1.4 [0.2-8.7] 0.70 
Mother HIV-positive (ref=Negative) 1.9 [0.9-3.7] 0.09 2.0 [0.6-6.8] 0.25 
Child delivered in health facility (ref=No) 0.3 [0.1-0.5] 0.00 0.3 [0.1-1.0] 0.06 
Timing of child birth (ref=before time) 0.3 [0.1-0.9] 0.02 0.5 [0.1-2.0] 0.32 
Mother told child had a growth problem (ref=No) 4.0 [1.5-10.6] 0.01 2.8 [0.8-9.8] 0.11 
Child ever breastfed (ref=No) 0.1 [0.0-0.2] 0.00 0.2 [0.0-0.9] 0.04 
Infant breastfed for more than 6 months (ref=No) 0.2 [0.1-0.5] 0.00 0.7 [0.2-2.9] 0.60 
Factors Associated with HIV Infection 
Disclosed HIV test result (ref = no) 0.3 [0.1-0.9] 0.04 0.3 [0.1-1.7] 0.18 
Mother told child had a growth problem (ref=no) 2.6 [1.1-6.4] 0.03 4.6 [1.5-13.5] 0.01 
Breastfeeding for 6+ months (ref=no) 2.3 [0.9-5.6] 0.06 2.3 [0.8-6.5] 0.12 
Started ART (ref=before BF) 
During pregnancy 1.5 [0.5-4.4] 0.49 1.2 [0.4-3.9] 0.75 
During breastfeeding 9.3 [2.6-32.9] 0.00 3.2 [0.6-15.9] 0.16 
Not on ART/After breastfeeding 6.3 [1.8-22.2] 0.00 1.9 [0.2-17.0] 0.57 
Received ART throughout breast feeding (ref=yes) 0.3 [0.1-0.8] 0.01 2.2 [0.4-12.8] 0.38 
Child was given first dose of NVP syrup within 3 
days after delivery (ref = no)  
0.3 [0.1-0.6] 0.00 0.3 [0.1-1.1] 0.08 
Child was given CTX to take daily beginning at 6 
weeks (ref = no) 
0.2 [0.1-0.6] 0.00 0.4 [0.1-1.5] 0.18 
Factors Associated with HIV-free Survival 
Disclosed HIV test result (ref = no) 2.9 [1.0-8.1] 0.04 4.9 [1.3-18.2] 0.017 
Delivered in a facility (ref = no) 2.3 [1.4-4.7] 0.00 1.7 [0.7-4.2] 0.22 
Mother told child had a growth problem (ref=no) 0.2 [0.1-0.5] 0.00 0.2 [0.1-0.5] <0.01 
When started ART (ref=before BF) 
During pregnancy 0.7 [0.3-1.6] 0.39 0.7 [0.3-1.8] 0.44 
During breastfeeding 0.1 [0.0-0.4] 0.00 0.3 [0.1-1.3] 0.11 
Not on ART/After breastfeeding 0.2 [0.1-0.6] 0.01 0.7 [0.1-4.2] 0.69 
Received ART throughout breast-feeding (ref=yes) 2.8 [1.3-5.9] 0.01 0.4 [0.1-1.8] 0.26 
Child was given first dose of NVP syrup within 3 
days after delivery (ref = no)  
4.0 [2.2-7.5] 0.00 2.1 [0.6-7.0] 0.22 
Child was given CTX to take daily beginning at 6 
weeks (ref = no) 









We found that HIV-free survival in Lesotho was 91.8%. Our results demonstrate 330 
the effectiveness of the Lesotho PMTCT program in averting HIV infection and deaths in 331 
children within the first 18-24 months of life after introduction of lifelong ART for all HIV-332 
positive pregnant women in 2013. Our finding corroborates with a systematic review of 333 
18 studies published between 2005 and 2015, that estimated HIV-free survival in a 334 
breastfed population found that 18-month HIV-free survival estimates were 89.0% (95% 335 
CI 83.9%, 94.2%) with maternal ART for six months (five studies) and 96.1% (95% CI: 336 
92.8%-99.0%) with maternal lifelong ART (three studies) [17]. HIV-free survival at 24 337 
months was 89.2% (95% CI: 79.9%-98.5%) for children whose mothers were on ART 338 
for six months (two studies) [17].  Among breastfed infants, HIV-free survival ranged 339 
from 87% (95% CI: 78%-92%) to 96% (95% CI: 91%-98%).  340 
Similarly, in a study in Eswatini, that reported HIV-free survival prior to the era of 341 
lifelong ART for pregnant and breastfeeding women in that country, HIV-free survival 342 
was 95.9% (95% CI: 94.1-97.2) though the authors reported a low death rate due to 343 
cultural sensitivities in collecting death data which may have impacted overall HIV-free 344 
survival [8].  345 
Although approaching elimination, the MTCT rate estimated in our study was 346 
5.7% [ 95%CI 4.0 – 8.0]. In the context of Lesotho, this shows much progress compared 347 
to the UNAIDS MTCT rates reported to be 12.7% (9.9-14.4) in 2019, and 30% in 2004 348 
[18]. As UNAIDS estimates are based on models, which make assumptions that may 349 
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UNAIDS estimates were based on PMTCT coverage of 77% (59-89) and early infant 351 
diagnosis coverage of 70% (60-90) (15). Further, assuming all children who died were 352 
HIV-infected, the percentage of children who died or were HIV infected was 8.2% 353 
[95%CI 6.2-10.8] versus 12.7% (9.9-14.4) for UNAIDS transmission. Although mortality 354 
among HIV-infected children is high, at most only 50% of HIV-infected children will die 355 
by their second birthday making it unlikely that all children who died were HIV-infected 356 
[4-7]. However, much needs to be done to ensure women living with HIV are diagnosed 357 
even ahead of their index pregnancy or ideally ahead of their first pregnancy because 358 
women who start ART before pregnant and are virally suppressed are less likely to 359 
transmit HIV to their babies in utero, perinatally or through breastfeeding. The MTCT 360 
rate in Lesotho remains unacceptably high, and over three years after the rollout of 361 
lifelong ART for HIV-positive pregnant women, the program has not yet achieved 362 
elimination (an MTCT rate of < 5% and 2% in breastfeeding and non-breastfeeding 363 
population respectively) [19]. In addition, our study shows differences between MTCT 364 
rates reported from clinical trials and real world rates. Former studies have consistently 365 
reported MTCT rates lower than 5% [18,20, 21]. 366 
One-third of HIV-infected children were diagnosed during the study. Eight of the 367 
ten children have been in contact with health system for various services. However, 368 
contrary to the recommendation that all HIV-exposed children should have the final HIV 369 
test at 18-24 months or six weeks after cessation of breastfeeding, this was not the 370 
case for the eight children [8]. Five out of ten had tested HIV-negative initially but had 371 
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been tested. This finding shows a need to look for HIV-infected children beyond PMTCT 373 
setting. In a systematic review of 26 papers, Cohn et. al found that HIV prevalence was 374 
highest in pediatric inpatient settings (21.1%, 95% CI: 14.9-27.3), nutrition centers 375 
(13.1%, 95% CI: 3.4-22.7), immunization centers (3.3%, 95% CI: 0-6.9), then pediatric 376 
outpatient (2.7%, 95% CI: 0.3-5.2). Symptom-triggered universal testing in pediatric 377 
outpatient settings had a diagnostic yield similar to that found in the inpatient ward 378 
(21.3%, 95% CI: 11.6-31.0 in triggered testing vs 20.9%, 95% CI: 13.5-28.3 in universal 379 
testing) [22]. In a recent paper, data from Cameroon showed nontraditional PMTCT 380 
entry points [adjusted odds ratio (aOR): 1.95; 95% confidence interval (CI): 1.36 to 2.80] 381 
was independently associated with HIV positivity among HIV-exposed children [23]. In a 382 
high prevalence country like Lesotho, optimizing testing with screening of all HIV-383 
exposed children at 18-24 months who do not have final HIV status will assist in 384 
diagnosing more children.  385 
Our study also explored factors associated with MTCT and/or death.  Factors 386 
associated with MTCT are well elucidated in the literature [22,24, 25]. Factors 387 
associated with HIV-free survival in Lesotho included HIV-positive mothers disclosing 388 
their HIV status and HIV-exposed infants taking cotrimoxazole prophylaxis. It can be 389 
hypothesized that women who disclosed their HIV status got more support to be 390 
adherent to their treatment [26,27]. HIV-exposed infants who had growth difficulties 391 
were more likely to be HIV-infected and/or to die.  392 
The limitations of the study include the fact that information for more than a 393 
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Although the team took all measures to verify the information in the handheld health 395 
records, in some instances such information was not available. However, our results 396 
remain valid considering the large sample size, which took these challenges into 397 
consideration.  398 
In addition, for several deceased children, we did not know their HIV status and 399 
the cause of death was not recorded in any home-kept document. This limitation did not 400 
have impact on our results because the study was measuring HIV-free survival and was 401 
not set to describe HIV-related deaths. 402 
Although the data collection was completed almost five years ago, the results of 403 
this study remain relevant especially because it is the first and so far the only 404 
community-based survey carried out in Lesotho to measure HIV-free survival. 405 
Conclusion 406 
Even in the context of lifelong ART among pregnant and breastfeeding women, HIV has 407 
a significant effect on survival among exposed children. HIV transmission to mothers 408 
and children continue to occur during breastfeeding period, therefore it is important to 409 
test mother-child pairs during the breastfeeding period while they attend routine clinics 410 
such as postnatal care, immunization clinics, outpatient and inpatient services. This 411 
study has shown that Lesotho has not reach elimination MTCT despite introduction 412 
lifelong ART for all HIV-positive women. Since this study measures the effectiveness of 413 
PMTCT program when the guidelines were just changed, it is expected that the 414 
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We recommend that the MOH develop a national registry that links HIV-exposed infants 416 
with their mother until final HIV status is ascertained at 18-24 months as per national 417 
guidelines. In addition, there is a need to repeat this study and triangulate data to 418 
measure impact of increased coverage of PMTCT services across Lesotho. 419 
 420 
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